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ABSTRACT 
In this Master’s dissertation, various doses of solubulized crude F4 fimbrial 
protein in conjunction with the adjuvants CpG ODN and porcine β-defensin 1 (pBD-1) 
were used to enhance the F4-specific intestinal immune response against Enterotoxigenic 
Escherichia coli (ETEC) F4 in post-weaned pigs. Using the mechanically shearing 
method we isolated the F4 fimbrial protein of ETEC with a molecular weight of 26 kDa. 
We verified this using a Western blot probed with a rabbit anti-F4 fimbrial antibody. 
Binding of the F4 fimbrial protein to the F4 receptor (F4R), present on the brush border 
of the villi in the small intestine of pigs, was demonstrated using an in vitro villus 
adhesion assay (IVVA). To demonstrate specificity rabbit polyclonal and mouse 
monoclonal anti-F4 antibodies, or the F4 protein were used to inhibit the adhesion of 
ETEC F4ac to F4R positive (F4Rpos) villi. 
To examine immunogenicity of the 500 micrograms (µg) of the F4 were 
administered into surgically created jejunal gut-loops in pigs. Three weeks later Peyer’s 
patches (PP) from immunized and control loops as well as gut-wall tissue were analyzed 
for their F4-specific antibody secreting cells (ASCs) by a modified enzyme linked 
immunosorbent spot (ELISPOT) assay. The F4-specific immune response in the serum 
was analyzed by an enzyme linked immunosorbant assay (ELISA). High numbers of F4-
specific ASCs were isolated from the loops of pigs that contained high levels of the F4R. 
Conversely nominal or low numbers of F4-specific ASCs were found in loops of pigs 
expressing low levels of the F4R or no F4R (F4Rneg). The IVVA was used to categorize 
the pigs into either F4Rpos or F4Rneg animals.  
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Next three different concentrations of the crude F4 protein 50, 250, and 500 µg in 
the loops of individual pigs were used to analyze if dose affected the F4-specific immune 
response. Interestingly dose had no effect on the magnitude of the response. Therefore we 
hypothesized that the F4-specific immune response in the loops could be enhanced 
through the use of the adjuvants CpG ODN 2007 and pBD-1. The F4 protein was co-
administered with either CpG ODN 2007 or pBD-1 and immune responses were assessed 
after 3 weeks. However neither CpG ODN 2007 nor PBD-1 at the doses used made an 
improvement in the immune response. Thus, these results demonstrated that the 
expression level of the F4R was the most important parameter for eliciting of the local 
immune response against the F4 protein. Furthermore our studies revealed that both 
F4Rneg and F4Rpos pigs responded to F4 immunization, however the former respond only 
nominally to F4-immunization in the loops. Moreover, an inverse relationship existed 
between the level of the F4-specific IgG in the serum and the F4-specific immune 
response seen in the loops. Thus our findings have important implications for oral 
vaccination using fimbrial based antigens (Ags) that utilize a receptor for their 
imunogenicity. Our results indicate that only animals with high levels of enterocyte F4R 
will have the ability to elicit high levels of protective F4-specific anti-fimbrial antibodies 
in their intestine after oral immunization. Therefore unless an effective adjuvant is 
available, animals with low to moderate levels of the fimbrial receptor in their small 
intestine will mount only weak immune responses making herd immunity after 
vaccination currently unattainable.    
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1.  REVIEW OF LITERATURE 
 
1.1 Diarrheagenic enterotoxigenic Escherichia coli (ETEC) 
  E. coli are motile Gram-negative bacteria that occupy the intestines of humans 
and animals as commensals or as pathogens. The genome consists of a singular circular 
DNA molecule of 4 x 106 base pairs with a molecular weight of ~ 2.5 x 109 Daltons. 
E. coli are serotyped based on their O lipopolysaccharide (LPS) and H (flagellar) surface 
antigen (Ag) profiles. Using a combination of O and H Ags there are over 10,000 
possible O:H serotypes of E.coli 1 . The K or capsular Ags, also used for serotyping, were 
historically used to represent fimbrial Ags because of their intimate association with the 
capsule. However, a new nomenclature was introduced which includes classifying 
fimbriae as F Ags. Fimbriae are important virulence factors that allow bacteria such as 
ETEC to adhere to mucosal surfaces preventing their removal by normal intestinal 
processes such as peristalsis. 
ETEC possess five different fimbrial subtypes, F4 (K88), F18, F5 (K99), F6 
(987P), and F41 2. F5, F6, and F41 fimbriae are predominantly associated with ETEC that 
cause scours in neonatal pigs, whereas the F4 and F18 adhesins are found on ETEC that 
predominantly cause post-weaning colibacillosis (PWC)3. Once colonization is 
established, ETEC can elaborate heat-labile (LT), heat-stable (ST), and East-1 
enterotoxins that act upon intestinal enterocytes causing secretory diarrhea. A variant of 
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ETEC known as ETEC/STEC (shiga toxin E. coli) can produce, in addition to LT and ST 
enterotoxins, Shiga-toxin that allows STEC to cause edema disease 4. Another type of 
diarheagenic E.coli that occasionally cause PWC are enteropathogenic E. coli (EPEC). 
EPEC cause attaching and effacing lesions, with effacement of microvilli and intimate 
adherence between the bacterium and the epithelial cell membrane resulting in diarrhea 
without elaborating toxins 4. 
 
1.2       Enterotoxins of ETEC F4 responsible for post-weaning diarrhea in pigs  
ETEC F4 infections are responsible for significant death and morbidity in 
neonatal and post-weaned pigs. ETEC expressing F4 fimbriae adhere to F4R on intestinal 
epithelial cells of F4R positive pigs (F4Rpos) only, resulting in colonization and 
subsequent enterotoxin secretion that leads to osmotic diarrhea in piglets 5. Depending 
upon the strain, ETEC F4 express heat-labile (LT), heat-stable (ST), and or EAST 1 
enterotoxins which cause diarrhea 3, 4. LT comes in two variants namely LT1 and LT2. 
The former resembles cholera toxin in its protein sequence, receptor targeting, and 
enzymatic activity, LT2 is not associated with disease 4, 6. LT1 is composed of 5 B 
subunits and one A subunit. The B subunit is responsible for binding to the receptor, 
whereas the A subunit contains enzymatic activity that stimulates production of cyclic 
adenosine monophosphate (cAMP). Increased levels of cAMP lead to a number of 
intracellular changes from cytoskeleton remodeling to increased activity in membrane 
transporters. These changes lead to a net secretion of chlorine and bicarbonate from 
intestinal cells, which eventually results in diarrhea 4, 6. ST also comes in two variants, 
STa and STb, both causing diarrhea. STa induces increased levels of cyclic guanlyate 
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monophosphate (cGMP) which activates anion channels facilitating the passage of 
chlorine out of the cell and into the lumen and leading to osmotic diarrhea 5, 6.  STa is 
also responsible for initiating intracellular cytoskelatal rearrangement which contributes 
to the intestinal secretory response 5. STb on the other hand is thought to stimulate 
increased production of serotonin and prostaglandins from intestinal cells resulting in 
increased levels of cAMP leading to diarrhea 7, 8. Lastly, East-1 found in association with 
LT1 and STb shares considerable amino acid sequence homology with STa and acts 
through the second messenger, cGMP, to cause diarrhea 9.  
 
1.3 The fimbriae of  the enterobacteriaciae  
Fimbriae are 0.5-1.5 microns long proteinaceous appendages peritrichously 
distributed at the surface of the bacterium that allow adherence of the bacteria to 
fimbriae-specific receptors 10. Between 100-300 fimbriae are present per bacterium. 
Fimbriae are classified according to the presence and position of various amino acids (aa) 
in the primary sequence of their major fimbrial subunit 11. The F4 fimbriae are placed 
into a class that do not contain the amino acid cysteine and contain a unique penultimate 
tyrosine at their carboxyl terminal end 11. Fimbriae are transcribed from operons that can 
have either a plasmid or chromosomal location 11. Transcription is either governed 
through regulatory molecules such as leucine responsive regulatory protein (Lrp) and 
catabolite activator protein (CAP), or is turned on or off through methylation-dependant 
phase variation via conserved DNA sequences known as GATC boxes 11-13. Regardless of 
the type of regulation, a number of environmental factors such as carbon availability, pH, 
and temperature influence fimbrial biosynthesis 14. Thus, fimbrial production in bacteria 
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is a multifactorial process involving global regulators, complex molecular mechanisms, 
and environmental conditions.  
 
1.4  F4 fimbriae of ETEC   
  The F4 fimbriae are lectins that bind to glycoprotein receptors located on the villi 
lining the small intestine of pigs 15. The genes faeA to faeJ are located on a plasmid and 
give rise to the corresponding proteins FaeA to FaeJ whose functions range from 
chaperones to building blocks for the F4 fimbriae 16. The F4 has a molecular weight of 
approximately 26 kDa as determined by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) 17. F4 fimbriae are ~ 1 um in length and are primarily 
composed of hundreds of repeating major subunits known as FaeG with a relatively small 
number of minor subunits interspersed throughout the structure. The minor subunits are 
not only part of the fimbrial structure but have important functions as well. For example, 
FaeC acts as a nidus for the addition of major subunits to begin fimbrial synthesis, FaeH 
and FaeF are interspersed throughout the fimbrial structure acting as scaffolding for the 
newly forming fimbriae 18. Further, the minor fimbrial subunit FaeA acts as a repressor of 
fimbrial synthesis, the functions of FaeB, FaeI, and Fae J are unknown, FaeD acts as an 
outer membrane usher, and FaeE represents a periplasmic chaperone 12, 16, 19, 20. The 
assembly of the F4 fimbriae begins with the expression of genes faeB through faeJ, 
whose rate of transcription is influenced by the level of the repressor FaeA. FaeC initiates 
F4 production as it acts as the nidus to which copious amounts of FaeG subunits are 
added with the minor subunits FaeH and FaeF added at integral locations throughout the 
  5
structure to permit proper elongation. The completed fimbriae is anchored to the 
membrane by FaeD (Figure 1.1). 
 
 
This complex biosynthesis can give rise to three fimbrial variants ‘ab’, ‘ac’, and 
‘ad’ of varying lengths. For example, F4ab and F4ad are 264 aa long, whereas F4ac is 
262 aa long 20. The distinction between the fimbrial variants is based on differences in 
their primary aa sequence, which results in variants that all share common ‘a’ epitopes 
but contain unique ‘b’, ‘c’, or ‘d’ determinants 20, 21. Aside from their unique antigenic 
differences, all three F4 variants have their receptor binding sites defined by interactions 
between their variable and conserved regions 18, 22. Interestingly all F4 fimbrial variants 
bind the F4R with equal avidity.     
Inner Membrane 
Outer 
Periplasm Minor Subunits 
Fae (F, H, D, E, I)
Major Subunit 
(FaeG) 
Figure 1.1 The expression of the major and minor subunits is followed by their 
incorporation into nascent fimbriae. The major subunit, FaeG, comprises the bulk of the 
fimbrial structure, with the minor subunits, FaeC and FaeF interspersed sparingly 
throughout. The minor subunit FaeE acts as a periplasmic chaperone with FaeD situated 
in the outer membrane acting as an anchor for the structure. 
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1.5 F4R   
The F4R is located in the villous brush border of susceptible pigs, where it   
facilitates binding of ETEC F4 to intestinal villi leading to colonization and diarrheal 
disease 23. The enterocyte F4Rs are a group of glycoproteins that vary in size with 
molecular weights ranging from 45-240 kDa 24, 25. These F4Rs have different specificities 
that allow them to bind one, two, or all of the ETEC F4 variants.  For example the 210 
and 240 kDa F4Rs bind F4ab and F4ac only, whereas F4Rs with molecular weights 
ranging from 45-70 kDa bind all three F4 variants 24, 25. The F4R is inherited in a 
Mendelian fashion with the gene for F4R expression being a dominant trait 23.  Its gene 
has been mapped to the region q41 -- q44 on chromosome 13 26.  
A reliable genetic test to categorize pigs as F4Rpos or F4Rneg is not currently 
available. Thus, the in-vitro villous adhesion assay (IVVA), an in-vitro test in which 
bacteria adhering to pig intestinal villi are enumerated to detect the presence of the F4R, 
is currently the only method to classify pigs as F4R negative (F4Rneg) or F4Rpos 27. 
Receptor classification, however, is more complex than a simple positive or negative 
categorization. For example, when the F4 variants ab, ac, and ad, are considered within 
the context of their adherence patterns, six adhesive phenotypes exist: phenotype A 
(binds all three variants), phenotype B (binds F4ab and F4ac only), phenotype C (binds 
F4ab and F4ad only), phenotype D (binds F4ad only), phenotype E (no F4R, therefore no 
binding of any variant of ETEC F4) and phenotype F (binds F4ab only) 28. This 
classification scheme enables us to determine which variants are endemic in a particular 
region of the world. For example, F4ad used to be commonly found in Europe, however 
today, F4ac is the most common type detected in Europe and throughout the world.  
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 The enterocyte F4R is expressed in pigs throughout their entire life time. 
However, their expression decreases with age making older pigs less susceptible to 
disease 2, 29. Interestingly the F4R is also found in pig intestinal mucus due to enterocyte 
turnover, their function is to bind ETEC F4 and aid in their removal from the intestine 30. 
Therefore, F4R in the mucus function to protect the neonatal pig from infection with 
E.coli. Presence of F4R in the mucus ceases by 6 months and declines significantly at the 
time of weaning 24, 29. In this study, we were solely concerned with the role of the 
enterocyte F4R in influencing the strength of the F4-specific immune response in pig gut-
loops.  
 
1.6 Clinical signs of PWC  
ETEC F4 infection in post-weaned pigs can result in diarrhea that typically begins 
16-36 hours post infection. Depending upon the severity of the diarrhea, feces can range 
in consistency from porridge like to liquid in severe diarrhea. Other clinical symptoms 
include fever, lethargy, discoloration of the ears and abdomen, with the tail and skin 
around the anus becoming wet and pasted with fecal material. Loss of appetite frequently 
occurs and, if prolonged, can result in retarded growth of the pig 2. Post mortem analysis 
can reveal an abnormal accumulation of blood and fluid within the intestine 2.  
A number of methods are used to diagnose ETEC F4 infection in post-weaned 
pigs including serotyping to identify the strain (i.e. O149, O8, O138, O141) based on Ags 
from the LPS, and unique epitopes found on different fimbriae (i.e. the major subunit is 
usually targeted) 31. PCR and DNA probes are used to detect the presence of virulence 
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genes such as fimbriae and toxins 32, 33. ELISA can also be used to serologically detect 
the presence of fimbriae or toxins 34.  
ETEC expressing F18 is also frequently found as a causative agent in PWC 35, 36. 
Therefore, some diagnostic techniques are required to distinguish between ETEC F4 and 
ETEC F18 strains as the causative agent for PWC. One method of differentiation is the 
use of PCR to detect fedA (the major pilus subunit gene) or faeG  the adhesins involved 
in adherence in ETEC F18 and ETEC F4, respectively 20, 37. The enterotoxins LT and ST 
are good markers to verify ETEC as the etiological agent in PWC because ETEC F4 
typically secretes LT whereas ETEC F18 is more commonly associated with the toxins 
STa and STb 3, 38. Immunological (ELISA and agglutination) or molecular (PCR, or DNA 
probes) methods could also be used to detect the presence of these proteins or genes, 
respectively 32-34. Therefore, to identify the strain(s) of ETEC responsible for an outbreak 
of PWC in pigs, more than one assay may be required.   
 
1.7  Vaccination against PWC 
A commonly used method to prevent disease in livestock is vaccination. For 
example, maternal immunization represents a way to protect neonatal pigs against ETEC 
infection. Sows are typically immunized with a combination of fimbrial Ags commonly 
associated with neonatal diarrhea, and produce antifimbrial antibodies that are passively 
transferred via colostrum and milk to suckling piglets 39. Unfortunately, this lactogenic 
immunity is no longer available to the post-weaned pig leaving it susceptible to ETEC 
infection. Thus, active immunization of the piglet is required to confer protection against 
PWC. Unfortunately, parenteral immunization of the piglet is not effective since 
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parenteral immunization fails to stimulate sufficient mucosal immune responses in the 
small intestine 40. Therefore, oral vaccines are required to elicit an intestinal mucosal 
immune response that can confer protection against PWC. 
 At the present time no commercial vaccine exists to prevent PWC even though a 
number of F4 fimbrial-based vaccines have been tested in pigs. For example, live 
attenuated E.coli expressing F4 fimbriae administered to 4 week old pigs has been tested 
but did not elicit enough memory F4-specific T cells that could be protective against 
challenge infection 41. However, if weaned pigs were co injected intramuscularly with  
levamisole, then orally vaccinated with live attenuated E.coli expressing F4 fimbriae 
some level of protection was achieved, thus adjuvant has the potential to enhance the 
immune response to the F4 in pigs 42. Several studies, however, have investigated the 
utility of using purified F4 fimbriae instead of attenuated E.coli as a source of the F4 Ag.  
Van den Broeck et al. 1999 vaccinated weaned pigs orally with purified F4 fimbriae and 
found it effective in stimulating the mucosal immune response as well as conferring 
protection against challenge with ETEC F4. Furthermore, the same authors demonstrated 
that only F4Rpos pigs responded to oral immunization with the F4 fimbriae 43. However, 
the efficacy of oral immunization with F4 fimbriae leads to variable outcomes, as our 
group carried out a similar vaccination/challenge experiment and found no enhanced F4-
specific immunity or protection against infection with ETEC F4 44. Nonetheless, the F4 
fimbriae or its major subunit FaeG continue to be tested for use in vaccines in a variety of 
ways. For example, pure F4 has been co-injected parenterally with an active metabolite 
of vitamin D into weaned pigs. Protection however was minimal and no F4-specific IgA-
ASC were found in the GALT of vaccinated pigs after immunization 45. Oral 
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immunization with purified F4 coated in an enteric formulation designed to allow the F4 
to reach the intestine in its most immunizing conformation is still being tested but F4 
dissociation from the coating polymer is currently a problem making this method of 
delivery ineffective 46. On the otherhand feeding diets containing egg yolk antibodies 
from laying hens hyper immunized with F4 fimbriae then incorporated into feed have 
been shown to reduce the severity of diarrhea and incidence of mortality due to ETEC F4  
47. Other methods involving feed are currently being developed for example the 
incorporation of the FaeG subunit into plants such as alfalfa and transgenic tobacco, 
could eventually be used for cheap large-scale production of the F4 fimbrial protein 48, 49. 
Currently, however, no method employing the F4 fimbriae either in its purified form or as 
a live vaccine is totally effective in preventing PWC in pigs.  
 
1.8  Mucosal immune system development and function in pigs  
The mucosal immune system in pigs develops within the first weeks of life. The 
development of the pigs SIg response in the lamina propria begins prenatally, unimpeded 
by passive maternal immunity, and continually develops until 3 months of age 50. Thus, 
the weaned pig is capable of eliciting an adaptive immune response in the gut as jejunal 
and ileal PPs are functional having a immunoglobulin repertoire of SIg that could 
theoretically afford protection against ETEC F4 50. 
 
1.9  Induction of F4-specific immunity in the pig intestine 
It is believed that once an Ag is delivered orally it will be taken up by specialized 
enterocytes known as M cells that overlay the PPs. M cells facilitate the transport of Ags 
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to dendritic cells (DCs) macrophages, and eventually to lymphocytes 51. The presence of 
professional Ag presenting cells in the dome region of PPs allows for stimulation of T-
helper cells, which provide specific help for IgA isotype production within the intestine 
52. Pigs have three different types of Peyer's patches, ilieal Peyer’s patches (IPP), jejunal 
Peyer’s patches (JPP), and spiral colon Peyer's patches 53. The pig JPP and IPP are both 
secondary lymphoid organs with the former having a more pronounced effect on immune 
induction than the latter 46, 50. Other tissues in the porcine gut can also function to induce 
mucosal immunity. For example, enterocytes take up Ag directly and pass it on to 
underlying APCs or present it via MHC I. However, presentation is limited because 
epithelial cells fail to express the co-stimulatory molecules needed to effectively present 
Ag 54. Furthermore, studies in mice have shown that Ag within the intestine can also be 
taken up by DCs that survey the lumen via transepithelial dendrites, thus acting as sites of  
induction 55, 56. 
 
1.10  Gut-loop model       
Conventional studies involving oral immunization with soluble F4 Ag in weaned 
pigs have revealed that the F4R is required to elicit an F4-specific immune response in 
the intestine of F4Rpos pigs 43. Unfortunately, trying to use this method to understand the 
relationship between the expression level of the F4R and the local F4-specific immune 
response in the gut is impractical and very costly. This is because the pig is an outbred 
species that would necessitate the use of several pigs in order to generate cohorts with 
similar expression levels of the F4R. Moreover, the process of orally delivering soluble 
F4 Ag to several of these pigs in itself poses a problem because it requires physical 
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manipulation of the pig, injecting the inoculum, and ineffective delivery of the F4 Ag to 
the small intestine after being subject to gastric and intestinal enzymes. Therefore, a more 
effective method is required to analyze the local immune responses within the small 
intestine. In the past, investigators created Thiry-Vella loops to examine these types of 
interactions 57. Unfortunately, this method was prone to bacterial contamination, villus 
atrophy, and epithelial hypertrophy, which limited their value 57. Mutwiri et al. 1999, 
originally developed the gut-loop model in fetal lambs consisting of a single sterile 
intestinal ‘loop’ to assess functionality of the JPP and IPP to Ag 58. Gerdts et al. 2001, 
using 4-6 month old sheep developed the model further by creating multiple intestinal 
‘loops’ to create independent sites useful for the analysis of the induction of multiple 
mucosal immune responses in the small intestine 59.   
 
1.11  Cytosine-Phosphate-Guanosine oligonucleotide (CpG ODN) 
1.11.1  Introduction to CpG ODN 
Our present day understanding about CpG ODN began to unfold over 100 years 
ago when scientists used extracts of bacteria to treat a variety of cancers, as reviewed in 
Wiemann and Starnes (2004) 60. However, the elucidation of the immune stimulating 
nature of the CpG motif was not apparent until the era of rational drug design that 
involved the use of antisense ODNs to turn off target genes as reviewed in Krieg (2002) 
61. Eventually after numerous studies involving antisense ODNs it became clear through 
structure and function analysis that the stimulatory effect was not due to secondary 
structure or palindromes, but rather a consensus motif of XCGY, where X is any base but 
C, and Y is any base but G 61. Interestingly the bases flanking the CpG dinucleotide 
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determine how immunostimulatory a CpG ODN will be in a given species 61. For 
example, in mice the best immunostimulatory CpG motif is GACGTT, whereas in 
humans the optimal motif is GTCGTT, which is also immunostimulatory in a number of 
other species such as cows, sheep, chickens, cats, and dogs 62, 63. Another important facet 
regarding the immune enhancing nature of CpG ODN is the composition of its backbone. 
For example, a phosphodiester backbone is susceptible to attack by nucleases reducing its 
half-life in the cell making it less immunostimulatory 64. On the other hand CpG ODN 
composed of a phosphorothioate (sulfur replaces one of the non-bridging oxygen atoms) 
and or a mixture of phosphorothioate/phosphodiester backbone are much more resistant 
to nuclease attack thereby increasing the ODNs half life and hence its immunostimulatory 
capacity   64.  
 
1.11.2  Cellular recognition of CpG ODN 
The innate immune system with the help of pattern recognition receptors (PRRs), 
such as the Toll-like receptors (TLRs), allow for the detection of various types of 
pathogens. Many microbes express markers called pathogen-associated molecular 
patterns (PAMPs) that are recognized by TLRs 65. For example, TLR1 in conjunction 
with TLR6 as well as TLR2 recognize microbial lipopeptides 66-68.  TLR3 recognizes 
viral dsRNA, TLR4 is the receptor for LPS, TLR5 recognizes flagellin, TLR7 and TLR8 
are implicated in viral-derived ssRNA, and TLR9 recognizes CpG DNA 69-74. Thus, the 
TLR family members recognize specific patterns of microbial components. TLRs are 
type 1 transmembrane proteins conserved between insects and humans which contain an 
extracellular portion characterized by a variable number of leucine rich repeats 69. The 
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cytoplasmic domains of TLRs are homologous to the mammalian intrerleukin-1 (IL-1) 
receptor and are known as the Toll-IL-1 R (TIR) domains 69. Specifically, once CpG 
ODN is taken up into the endosome in a sequence non-specific process it signals via 
TLR9 after endosomal maturation 71.  
 
1.11.3  Signaling through TLR9 pathway  
Signaling by TLR9 is initiated through its TIR-domain in a MyD88 dependent 
pathway 72. MyD88 binds to the cytoplasmic portion of TLR9 through its interaction with 
individual TIR domains, which in the case of CpG stimulation would be the TIR of TLR9 
expressed in a late endosome 65, 73, 74. Upon stimulation, MyD88 recruits IL-1 receptor-
associated kinase (IRAK) of which 1 and 4 are critical in recruiting the next downstream 
molecule tumor necrosis factor receptor (TNFR)-associated factor 6, (TRAF6) 75. TRAF6 
activates downstream molecules that results in inhibitor of nuclear factor kappa B (IκB) 
degradation, allowing nuclear factor-kappa B (NF-κB) to move to the nucleus resulting in 
the activation of proinflammatory cytokines and several co stimulatory molecules 76. 
 
1.11.4  Cells which respond to CpG ODN stimulation 
CpG ODN stimulate a variety of murine and human leukocytes for example, B 
cells, bone marrow derived DC (BM-DC), monocytes/macrophages, and NK cells 60, 77-82. 
T cells do not contain TLR9 and thus respond indirectly to CpG ODN if their T cell 
receptor (TCR) is cross linked first, i.e. as was demonstrated when CpG ODN was used 
in conjunction with anti-CD3 83. Unlike mice, humans have a small subset of cells that 
contain TLR9 and thus can respond directly to CpG ODN; these are plasmacytoid 
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dendritic cells and B cells 84, 85. Two distinct classes of CpG ODN clusters have emerged 
as defined by their ability to preferentially stimulate either plasmacytoid dendritic cells 
(pDCs) or B cells in humans 86, 87. Class A ODNs stimulate pDCs to secrete IFN-α and 
support NK cell production of IFN-γ 86. Class B ODNs activate monocytes/dendritic cells 
to produce IL-6 and B cells to proliferate and secrete IgM 87. A third class known as class 
C ODN has stimulatory properties of both classes and stimulates B cells to secrete IL-6 
and pDCs to produce IFN-α 88. Various farm animals also respond to CpG ODN 
stimulation 89, 90. For example, PBMCs from pigs respond optimally to certain CpG 
motifs by increasing their expression of IL-6, IL-12, TNF-α, and IFN-γ 63, 91, 92. 
Therefore, if an optimal porcine CpG ODN motif is used, pig leukocytes will respond, 
thus making pigs a good animal model to study the effects of CpG ODN.  
 
1.11.5  Cytokines induced by CpG ODN 
The type of cytokines induced by CpG stimulation varies depending upon the type 
of immune cell that is stimulated. In mice CpG ODN causes B cells to produce IL-6 and 
IL-10 81, 93. Mouse DCs and macrophages produce IL-12, IL-6, and TNF-α, with DCs 
primarily producing IL-12, and in macrophages IL-6, and TNF-α production  
predominates 71, 94. Both T cells and NK cells in mice indirectly respond to CpG ODN by 
producing IFN-γ, which is also the only cytokine produced by human NK cells after CpG 
stimulation 80, 83, 95. Human B cells secrete IL-6, whereas pDCs primarily produce IFN-α 
62, 82 . In pigs the cytokines produced by CpG ODN stimulation of pDCs and B cells are 
not unlike those seen in their human analogs in that pDCs produce IFN-α, and B cells 
produce IL-6 91, 96. Besides the secretion of cytokines, CpG ODN also stimulated the 
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production of increased levels of MHC class II and the co stimulatory molecules B7-1 
and B7-2 on both DCs and B cells 60, 97. Thus by incorporating the adjuvant CpG ODN in 
our gut-loops in conjunction with the F4 Ag, the potential exists to enhance B cell 
proliferation and therefore the production of F4-specific IgA 98.  
 
1.11.6  Adjuvanting effect of CpG ODN  
It has been demonstrated that CpG ODN is immunostimulatory for B cells, pDCs, 
monocytes/macrophages, NK cells, and T cells in mice and humans 60, 62, 71, 80-83, 94, 95. 
Numerous studies have also shown that farm animals or PBMCs from these animals 
respond to CpG ODN 89, 90, 99. In pigs, CpG ODN has been shown to induce PBMCs to 
proliferate and secrete cytokines and interferons 100, 63, 91, 92. Alcon et al. 2003, by co-
delivering the outer membrane lipoprotein A of Actinobacillus pleuropneumoniae (App) 
with CpG ODN 2007 as an adjuvant in a novel lipid based formulation, elicited 
protection in pigs against infection with App. In other studies, the CpG motif ATGCAT 
has been shown to be mitogenic for pig B cells and effective as an adjuvant in a DNA-
vaccine against pseudorabies virus (PrV) that provided protection against lethal PrV-
infection 101.  
 
1.12  Cationic antimicrobial peptides (AMPs)  
1.12.1  Defensins and cathelicidens  
AMPs are present in a variety of animal species. In mammals for example, two 
abundant classes are the defensins and cathelicidens 102. Cathelicidens are a structurally 
diverse group of peptides with the exception of containing an N-terminal cathelin and C-
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terminal microbicidal domain 64, 103. Defensins on the other hand are all structurally 
similar in that they possess six invariant cysteine residues that form three intramolecular 
disulphide bonds 104. Both cathelicidins and defensins are antimicrobial for a number of 
pathogens and expressed by a variety of tissues including neutrophils 105-107. Moreover, 
they are chemotactic for a small subset of leukocytes, thus believed to link the innate with 
the adaptive immune response 108-110. However, defensins unlike cathelicidins, do not 
bind endotoxin, are abundant in the small intestine, and are chemotactic for iDCs 106, 110.  
 
1.12.2  Defensins: Classes, structures, and properties  
Defensins can be subdivided into three classes α, β, and θ, based upon the position 
of their intramolecular disulfide bonds. For example α-defensins contain 3 intramolecular 
disulfide bonds between conserved cysteines in positions 1-6, 2-4, 3-5, and are alpha 
helical in structure 111. The β-defensins on the other hand contain β sheet elements with 
cysteine bonds in positions 1-5, 2-4, and 3-6, whereas θ-defensins also contain three 
cysteine bonds but are cyclical in nature 112, 113. Defensins range in size from 29-35 amino 
acids for α -defensins, up to 47 amino acids for β-defensins, and 18 amino acids for θ-
defensins 113-115. Defensins are amphipathic (hydrophilic and hydrophobic properties) 
molecules that contain several arginine and lysine residues that impart a net positive 
charge on the molecule 114, 116. These properties make defensins microbicidal allowing 
them to bind and subsequently penetrate negatively charged bacterial membranes 
resulting in their lysis 117. Defensins are active at concentrations ranging from 1-100 
ug/ml, but all classes of defensins except θ-defensins have reduced antimicrobial activity 
at physiological concentrations of salt 117.  
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1.12.3  Recognition of β-defensins and consequences of their release  
Defensins aside from their direct antimicrobial activity behave like chemokines. 
Specifically human β-defensins 1 and 2 are chemotactic for both human resting memory 
T cells and iDCs by interacting with chemokine receptor 6 (CCR6) 110. Moreover they 
cause iDCs to mature thus promoting more effecient Ag presentation at inductive sites 
118. Therefore, β-defensins by facilitating the recruitment of a number of leukocytes 
notably iDCs, to the site of infection make them a natural adjuvant to be used in our gut-
loops 118, 119.  
 
1.12.4  β-Defensin as an adjuvant  
The defensins innate property to act as an adjuvant has been used to enhance the 
immune response to a number of academic Ags, and human immunodeficiency virus-1 
glycoprotein 120 (HIV gp120) 120-122. Specifically, Biragyn et.al demonstrated that an 
HIV gp120 specific mucosal, systemic, and cytotoxic T lymphocytes (CTL) immune 
responses could be achieved against HIV gp120 by using a plasmid vaccine containing a 
β-defensin fused to HIV gp120 120. Thus, it has been shown that β-defensins act as 
adjuvants to enhance Ag specific immunity in the small intestine and are chemotactic for 
iDCs. Therefore, we used pBD-1 to adjuvant the F4-specific immune response in our gut-
loops.  
 
1.12.5  pBD-1 location and expression 
The porcine β-defensin-1 is a small antimicrobial peptide of 42 amino acids in 
length that is produced as a 64 aa prepropeptide requiring cleavage in order for activation 
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to occur 123. It is expressed in a variety of tissues such as the tongue (highest mRNA 
levels), respiratory and gastrointestinal tract 124. Although developmentally regulated, 
pBD-1 was originally believed to be constitutively expressed however, it has recently 
been shown that its expression is inducible after bacterial infection 125. It is microbicidal 
against a number of pathogens but high physiological salt concentrations like that seen in 
cystic fibrosis (120-170 mM) halt its activity 126. Interestingly pBD-1 resembles human 
β-defensin-2 (HBD2) in its amino acid sequence and sites of expression 123. The HBD2 is 
known to induce the migration of iDCs and memory T cells 110.  
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3. THE RESEARCH OBJECTIVES AND HYPOTHESIS 
 
ETEC represent an important cause of neonatal and PWC, both of which are 
responsible for significant economic losses to the swine industry. ETEC strains causing 
PWC express a virulence factor known as the F4 fimbriae, which is used for adherence 
and subsequent colonization that leads to diarrhea. At weaning the piglet is susceptible to 
diarrhea because maternal antibodies are no longer available to the piglet; therefore active 
immunization is required to induce protective immunity. Moreover the induction of an 
immune response in the small intestine is required for protection against the disease and 
therefore oral vaccines that can induce mucosal immunity in the intestine are required. 
Several vaccination strategies have been tried in young piglets including parenteral 
immunization with live attenuated or inactivated ETEC F4, and edible vaccines such as 
alfalfa expressing the F4 Ag. With the exception of immunization with purified F4 
fimbrial protein, most of the approaches have failed to provide protection against ETEC 
F4 challenge infection.   
Interestingly, the induction of F4-specific mucosal immunity using the F4 appears 
to occur in F4Rpos pigs only. Thus, a more detailed analysis of the induction of F4-
specific local immunity in the small intestine is needed. Here we used an intestinal-loop 
model to investigate the induction of F4-specific immune responses in the intestine of 
post-weaned pigs. Surgically created jejunal loops were injected with crude F4 
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fimbrial protein and local immune responses were assessed three weeks later by 
quantifying the number of F4-specific ASCs isolated from PPs and gut-wall in the loops. 
By using the gut-loop model we were able to analyze multiple doses and vaccine 
formulations within the same animal reducing the variability associated with a large out-
bred animals such as the pig.  
The four objectives of this study including the hypothesis are listed below:  
1) The first objective was to elicit an F4-specific immune response in surgically 
created gut-loops of three to four week old pigs. To this end loops were injected with 
purified F4 fimbriae and immune responses against the F4 fimbrial protein were analyzed 
by isolating the F4-specific ASCs from PPs and gut-wall in our loops. A modified 
ELISPOT assay was used to determine the number of F4-specific ASC that were present 
per 5 x 106 cells. Serum was collected on days 0, and 21, and F4-specific serum IgG was 
analyzed for using an ELISA.  
2) The next objective was to investigate whether or not increasing the dose of the 
F4 protein would result in increased F4-specific immune responses in the gut-loops. 
Three doses of the F4 protein 500 µg, 250 µg, and 50 µ/loop were injected into separate 
loops to test this hypothesis. The ELISPOT was used to measure the F4-specific Ig ASC 
in the loops, and F4-specific responses in the serum were analyzed using ELISA. 
3)  Failing to see an increase in the F4-specific immune response due to changes 
in the dose we hypothesized that the local immune response in the small intestine could 
be enhanced by co-administration of the F4 with the adjuvant CpG ODN 2007 into the 
loops. This enhancement would be attributable to CpG ODN improving B-cell function 
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in the lamina propria and PPs of our loops as well as recruitment of more iDCs to the 
loops.  
4) Lastly, we tested the adjuvant pBD-1 co-administered with the F4 protein into 
our gut- loops. We hypothesized that pBD-1 would enhance the F4-specific immune 
response in the loops by attracting iDCs and hastening their maturation. 
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3.  THE IMPORTANCE OF THE F4 RECEPTOR IN RECEPTOR ELICITING 
MUCOSAL IMMUNE RESPONSES AGAINST ESCHERICHIA COLI IN PIGS 
 
 
3.1 Abstract 
 
ETEC F4 is an important pathogen in both humans and animals. In pigs, ETEC F4 
causes post-weaning colibacillosis (PWC), a disease responsible for significant economic 
losses to global swine production. The development of clinical disease depends on the 
presence of the F4 fimbriae receptor (F4R) on epithelial cells in the intestine and only 
pigs that express the F4R display clinical disease. Effective prevention depends on the 
induction of local immunity in the small intestine. However, mucosal vaccines against 
PWC are currently not available and treatment is limited to the use of antibiotics. Here, 
we analyzed the role of the F4R for the induction of local immune responses in an in vivo 
gut-loop model in pigs. Various doses of purified F4 were administered into surgically 
created intestinal-loops and local immune responses were assessed by determining the 
number of F4-specific IgA- and IgG-ASC. In addition, the effect of the adjuvants CpG 
ODN and pBD-1 were assessed for their immunopotentiation of the crude F4 protein in 
our loops. The F4-specific immune responses were detected in immunized loops from 
both F4Rpos and F4Rneg animals. However, the magnitude of the immune response was 
dependent on the level of F4R-expression and was significantly stronger in F4Rmod to high 
pigs compared to F4Rneg to low pigs. Thus, our results demonstrate 
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that the expression level of the F4R is the most important factor for successful induction 
of mucosal immune responses against ETEC F4 infections in pigs.  
 
3.2  Introduction 
ETEC represent an important cause of neonatal and PWC, both of which are 
responsible for significant economic losses to the swine industry 1. ETEC strains causing 
PWC express virulence factors known as fimbriae (F4, F18, 987P) and enterotoxins (LT, 
ST, EAST-1), which are responsible for bacterial adherence and diarrhea, respectively 1. 
F4 fimbriae are proteinaceous bacterial appendages, which are composed of major 
(FaeG) and minor subunits (FaeC, FaeF, FaeH, and FaeI) 20. FaeG mediates binding to 
the F4R, a group of glycoconjugates expressed on intestinal epithelial cells. Binding to 
the F4R is a requirement for bacterial adherence to the intestinal surfaces, and as a 
consequence, PWC occurs only in F4Rpos pigs but not in F4Rneg pigs 2-6. Several 
strategies to prevent ETEC infections in pigs have been developed including maternal 
immunization, vaccination with live attenuated or inactivated bacteria, treatment with 
antibiotics, and selective breeding of F4Rneg pigs 7, 8. Although maternal immunization 
represents an effective means of controlling colibacillosis in neonatal pigs, sufficient 
levels of maternal antibodies are no longer available in post-weaned pigs. Thus, active 
immunization of the newborn piglet is required to induce protective immunity against 
PWC 9, 10. However, effective vaccination must induce a mucosal immune response in the 
small intestine, as high levels of SIgA are required to protect against disease. For 
example, intramuscular immunization with purified F4 in combination with 1α, 25-
dihydroxyvitamin D3 induced strong systemic immune responses in F4Rpos pigs, but the 
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induction of local immunity, and especially the induction of secretory IgA (SIgA) at the 
intestinal surfaces, was not achieved to any degree. Consequently, pigs were not 
protected against subsequent challenge infection 11. In contrast, van den Broeck et al. 
(1999) showed that oral vaccination with purified F4 resulted in protection against 
challenge infection, demonstrating that the induction of mucosal immunity is critical for 
protection against the disease. However, the induction of protective mucosal immunity is 
complicated by a number of factors including the fact that only F4R+ pigs responded to 
vaccination 12. In addition, several factors such as genetics, nutritional status, and stress 
can play an important role in the disease outcome and further complicate the 
development and evaluation of vaccines 13. Various strategies for mucosal vaccination 
against ETEC F4 have been tested including immunization with purified F4, recombinant 
FaeG monomers, edible F4 vaccines, incorporation of F4 into enteric-coated pellets, and 
immunization with attenuated live bacteria 3, 5, 12. However, since most of these 
vaccination strategies induced only partial protective immunity, a more detailed analysis 
of the induction of F4-specific local immunity in the small intestine is needed.  Here, we 
used an intestinal-loop model to investigate the induction of F4-specific immune 
responses in the intestine. Surgically created jejunal loops were injected with crude F4 
fimbrial protein and local immune responses were assessed three weeks later by 
quantifying the number of F4-specific ASCs. Our gut-loop model facilitated the analysis 
of multiple immune responses within the same animal and therefore reduced the 
variability in results contributed by individual pigs 14. Consequently, this model allowed 
testing of different doses and vaccine formulations within the same animal and same F4R 
background. Using this model, our objectives were to evaluate the role of the F4R during 
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the induction of F4-specific immunity in the small intestine, to identify a dose that elicits 
the strongest F4-specific immune response, and to analyze the effect of two potential 
mucosal adjuvants, namely CpG ODN and a chemically synthesized porcine beta-
defensin 1 (pBD-1). Both adjuvants were chosen because of previous evidence for 
adjuvant activity in various animal models 15-19. 
 
3.3  Materials & Methods 
3.3.1  Isolation of crude F4 fimbriae 
  The E. coli isolate JG280, serotype 0149:H10:F4ac, LT+STaSTb (obtained from 
Dr. Carlton Gyles, U. of Guelph) was cultured with shaking (85 rpm) in tryptone soy 
broth (Difco Laboratories, Sparks MD USA) at 370 C for 18 h. Bacteria were collected by 
centrifugation (4096 g, 15 min) followed by washing with phosphate-buffered saline 
(PBSA; 150 mM, pH 7.4), and further centrifugation at  4096 g for 15 min. As described 
by van den Broeck et al. (1999) the F4 fimbriae were isolated by homogenization of the 
resuspended bacteria using a Polytron® pt 3100 (Kinematica, AG) at 24000 rpm for 20 
min at 4oC. Centrifugation at 8074 g for 20 min and 16846 g for 40 min were carried out 
to remove large fragments. The solubilized fimbriae, present within the supernatant were 
precipitated with 40% ammonium sulfate overnight. The precipitate was centrifuged at 
16846 g for 40 min, dissolved in Tris-HCl (100 mM, pH 7.4) plus 2M urea and 
subsequently dialyzed overnight against ultra-pure water to yield the crude F4 protein. 
The protein concentration of the isolated crude F4 was determined by the bicinchoninic 
acid reaction using bovine serum albumin as a standard (MJS Biolynx Inc., Brockville, 
Ontario). Purity of the crude fimbrial preparation was assessed by electrophoresis on 12% 
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SDS-PAGE gel and by western blot using a polyclonal rabbit anti-F4 serum (obtained 
from Dr. John Fairbrother, University of Montreal, Canada). 
 
3.3.2  Production of pure F4 protein 
Twenty-five ml of crude F4 fimbriae derived from the E. coli isolate JG280, 
serotype 0149:H10:F4ac, LT+STaSTb using the mechanical shearing method, was subject 
to purification by SDS PAGE and electroelution. Two (16 x 20 cm) 12% acrylamide 
resolving gels were placed into a Large Format Vertical Electrophoresis chamber (Bio-
Rad Laboratories, Mississiuaga, Ontario, Canada) and loaded with 12.5 ml of crude 
fimbrial protein. A voltage of 200 for 8 hours was required to separate the F4 protein into 
a discrete band. The gels were subsequently stained with Coomassie Brilliant Blue 
staining solution (EM SCIENCE, Gibbstown, New Jersey, USA) and then immediately 
destained. The gels were then placed onto 20 x 20 cm glass plates and the F4 protein 
bands approximately 2 x 20 cm in size, distinguishable from all other bands due to their 
width and deeper staining, were then cut away from each gel with a scalpel and 
subsequently cut into six 2 x 5cm strips and placed into the Elutrap device sample 
chamber with Tris-glycine (25mM Tris, PH 8.3; 192mM glycine; 0.1% Sodium Dodecyl 
Sulphate) buffer. A voltage of 200 was applied for 4 hours, after which the eluate was 
collected and the amount of the pure F4 protein determined by the bicinchoninic acid 
reaction using bovine serum albumin as a standard (MJS Biolynx Inc., Brockville, 
Ontario, Canada). SDS PAGE and WESTERN Blot analysis confirmed the purity. The 
eluted F4 protein was immediately stored at -80oC.  
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3.3.3  In vitro villous adhesion assay  
In order to determine the presence of the F4R on the mucosal epithelium, IVVAs 
were performed as described before 12. Fifteen cm sections of jejunum were excised at 
the time of surgery. Collected segments were immediately processed to obtain the villi. 
The segments were opened along the mesentery and washed in PBSA. The villi were 
scraped off into Krebs–Henseleit buffer containing 1% formaldehyde at 4oC and used 
immediately or stored at 4oC overnight. Villi were washed in Krebs–Henseleit buffer 
without formaldehyde (at 4oC) before 4 × 108 ETEC F4 were added  to  an  average of 50 
villi in 0.5 ml PBS with 1% D-mannose and incubated at RT for 1 h while gently shaking 
at 80 rpm. Adherence of the bacteria to the villi was examined by phase contrast 
microscopy at a magnification of 40x and 100x and determined by counting the number 
of bacteria adhering along a 50 um length of villous brush border at 20 different places of 
at least five different villi, after which the mean bacterial adhesion per 250 um villous 
lengths was calculated. Adhesion of more than 40 bacteria per 250 um villous was 
designated as F4Rhigh (+++), 25-39 bacteria as F4Rmedium (++), 6-24 bacteria as F4Rlow (+), 
and less than five bacteria per 250 um villous length was regarded as F4Rneg (see Figure 
3.2) 
  29
A  
  
                                                                      
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.1.  The in vitro villus assay (IVVA). Binding of ETEC F4 to a F4Rneg pig (A) and a 
F4Rhigh (B.) Area of approximately ~175 µm in length was assessed by phase contrast 
microscopy (1000x) for the presence of bacteria adhering to the brush border. 
Categorization: (F4Rhigh (+++) > 40 adhering ETEC, F4Rmed (++) 25-39 adhering ETEC, 
F4Rlow (+) 5-24 adhering ETEC, F4Rneg  < 5 adhering ETEC. 
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3.3.4  The inhibition of ETEC F4 to F4-specific brush border receptors by 
F4ac fimbriae, F4ac-specific rabbit polyclonal, and mouse monoclonal antibodies 
The IVVA used villi that had been scraped off from 15 cm jejunal sections of an 
F4Rpos pig, and stored at 4oC in Krebs–Henseleit buffer containing 1% formaldehyde. 
These villi were then washed in Krebs–Henseleit buffer without formaldehyde (at 4oC) of 
which aliquots of approximately 50 villi were added to separate reaction tubes containing 
500 ul of PBS with 1% D-mannose plus one of the following amounts of F4ac fimbriae 0, 
2, 10, 20, or 50 µl; and 2, 5, 10, or 20 µl, of F4 ac-specific polyclonal rabbit serum 
(rPAb) (obtained from F4 immunized rabbits at VIDO), and 2, 5, 10, or 20 µl, F4 ac-
specific monoclonal mouse serum (mMAb) (Kindly provided by Frank Verdonk, Ghent 
University, Merelbeke, Belgium) 20. An irrelevant mouse IgG antibody (Caltag Labs; 
Burlingame, California) and non-immunized rabbit serum were used as negative controls 
for the F4ac-specific mMAb and rPAb IVVA inhibition experiments respectively. These 
mixtures were shaken at 80 rpm at room temperature for 60 minutes, at which time 4 × 
108 ETEC F4ac bacteria were added and shaken at 80 rpm for one hour at room 
temperature. The adherence was determined by counting the number of bacteria adhering 
along a 50 um length of villous brush border at 20 different places from at least five 
different villi, after which the mean bacterial adhesion per 250 um villous lengths was 
calculated. The inhibition of ETEC F4 binding to villi by the various concentrations of 
F4ac protein was examined by phase contrast microscopy at a magnification of 1000x. 
The percentage adhesion was calculated by multiplying by 100 the ratio between 
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adhesion with and without F4ac pre-incubation. One hundred minus this adhesion 
percentage results in the inhibition percentage. 
 
3.3.5  Animals, surgery, and post-surgical treatment  
All animal experiments were conducted in accordance with the Guide to the Care 
and Use of Experimental Animals, provided by the Canadian Council on Animal Care. 
Three to four week old pre-weaned piglets, obtained from the Prairie Swine Centre, 
University of Saskatchewan, were housed at the Vaccine & Infectious Disease 
Organization (VIDO) animal facility. The pigs were fasted for 12-18 h prior to surgery 
and pre-medicated by intramuscular injection of xylazine (2 mg/kg) and ketamine (20 
mg/kg). Anesthesia was maintained using isoflurane. Intestinal segments were surgically 
created as described before 14. Briefly, an intestinal segment containing six to eight 
Peyer’s patches (PPs) was separated from the normal intestine, flushed with 100 ml of 
sterile phosphate-buffered saline without Ca++ and Mg++ (PBSA) to remove contents, and 
injected with 60 ml PBSA containing metronidazole (Abbot Labs Ltd, Saint-Laurent, 
Quebec, Canada) (250 mg) and enrofloxacine (Bayer Inc., Toronto, Ontario, Canada) 
(200 mg). In addition, a 15 cm long piece of jejunum was removed for the in vitro villous 
adhesion assay (IVVA). The patency of the non-segment intestine was re-established by 
an end-to-end anastomosis. The metronidazole and enrofloxacin solution was removed 
with a PBSA flush prior to closing both ends of the intestinal segment with an inversion 
type suture pattern. PP were macroscopically identified and silk ligatures were tied 
proximal and distal to each PP to create ~20 cm isolated segments containing a PP loop 
separated by interspaces of various lengths that lacked PP. All loops and interspaces were 
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injected with PBSA containing 1 mg of ampicillin (Sigma Aldrich Co). The F4 or the 
combination of F4 with either CpG ODN 2007 (obtained from Merial Limited, Duluth, 
Georgia) or the pBD-1 was injected in a volume of 1 ml PBSA into each loop. Control 
loops received 1 ml PBSA instead. The proximal loop was marked by an additional 
suture and a map was drawn for the identification of immunized and non-immunized 
control loops. The intestine was replaced into the abdominal cavity and the surgical 
incision in the abdominal wall was closed in three layers. Post-operatively, flunixin 
meglumine and enrofloxacin were administered for three and five days, respectively (see 
Figure 3.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.  The Gut-loop model was adapted for use in 3-4 week old pigs (Gerdts et al, 
2001), which allowed us to analyze the induction of the local immune responses against 
the F4 Ag alone or co injected with the adjuvants CpG and porcine β-defensin-1 (pBD-1) 
into loops with Peyer’s patches. After 3.5 weeks, F4- specific ASC were isolated from 
the Peyer’s patches or gut wall and analyzed using a modified ELISPOT assay.  
 
 
 
  F4 (Loop) 
F4 + Adjuvant  
(Loop) 
PBSA 
(Loop) 
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3.3.6  Samples and tissue collection 
To determine serum antibody titers against F4, serum was collected from each pig 
the day before surgery and at weekly intervals following surgery. The pigs were 
euthanized three weeks after surgery by lethal injection (Euthanyl, MTC Pharmaceuticals 
Ltd, Cambridge, Ontario) and intestinal loops and mesenteric lymph nodes were 
immediately placed into cold PBSA. Each loop was subsequently injected with 10ml 
PBSA + 250 µl of 100 mM phenylmethylsulphonylfluoride (PMSF). Loops were cut 
open along the mesenteric border and contents were collected into 50 ml centrifuge tubes 
(Corning, Corning, NY, USA). PPs were dissected from each loop and placed separately 
in 10 ml ice-cold PBSA containing 1% antibiotic/antimycotic (penicillin G sodium 
10,000 units/ml, streptomycin sulfate 10,000 ug/ml, amphotericin B 25 ug/ml) (Gibco 
BRL, Burlington, ON, Canada). Contents were thoroughly mixed by vortexing with 10 
ml PBSA and 200 ul 100 mM PMSF (Sigma-Aldrich, Oakville, ON, Canada) and 
particulate material was removed by centrifugation at 600 g for 15 min. Supernatants 
were stored at −70 °C.  
 
3.3.7  Isolation of PP cells 
Follicles and cells from the interfollicular region of the PP were obtained by 
scraping the mucosal surface from the underlying muscularis externa into PBSA + 0.1% 
EDTA (BDH, Toronto, Ontario). Large fragments of the mucosa were removed before 
subjecting the remaining follicles and cells to vigorous pipetting to create a single cell 
suspension 14. This suspension was filtered through a 40 micron nylon mesh cell strainer 
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(Becton Dickinson Labware, NJ, USA), then subsequently washed in PBSA and 
resuspended in RPMI medium (Gibco BRL, Burlington, ON, Canada) supplemented with 
10% fetal bovine serum (FBS; Gibco BRL) and 50 uM 2-mercaptoethanol (Sigma-
Aldrich). All subsequent assays employed this medium. Using the trypan blue exclusion 
method, viable cells were counted using a Neubauer haemocytometer. Cells were 
resuspended in medium at a concentration of 5×106 cells/ml, which were subsequently 
used in the ASC assay. 
 
3.3.8  Isolation of intraepithelial and lamina propria lymphocytes   
Pigs were euthanized with an i.v. injection of pentobarbital sodium (Euthanyl, 
Bimeda, MTC, Cambridge, ON, Canada) and the gut-loops and interspaces were 
collected and placed immediately into cold PBSA containing antibiotic-antimycotic 
solution (Gibco, Invitrogen, Inc., Grand Island, NY, USA). Another intestinal portion of 
15-20 cm was cut along the mesenteric border, blotted on paper towel and washed in 
PBSA. Subsequently, this intestinal segment was cut into small (0.5 cm2) pieces and 
placed into a 50 ml Teflon-Beakers containing 25 ml of a solution containing 5% fetal 
bovine serum (FBS, SeraCare Life Sciences, Inc., Oceanside, CA, USA), 0.01M Hepes 
Buffer (Sigma, St Louis, MO, USA), 50 µg of Enrofloxacin, and 2 mM EDTA (EMD 
Chemicals, Gibbstown, NJ, USA). This solution was denominated PBSA-buffer-EDTA. 
Approximately 40 ml of non-segment small intestinal contents were collected in 50 ml 
tube. All these samples were kept in ice until processed. 
The Teflon-beakers containing the intestinal pieces were incubated for 90 minutes 
on a magnetic multi-stirrer, set on moderate agitation, at 37˚C. The supernatant, which 
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contained intraepithelial lymphocytes and epithelial cells, was collected by filtering the 
tissues fragments and mucous through a plastic strainer. This filtered supernatant was 
centrifuged at 1200 rpm for 15 minutes at 4˚C. The pellets were re-suspended in PBSA-
buffer without EDTA and centrifuged as above. This washing step was repeated twice. 
The remaining tissue fragments were incubated for 90 minutes in PBSA-buffer 
containing 250U/ml of collagenase type 1 (Worthington Biochemical, Lakewood, NJ, 
USA) at 37˚C and moderate agitation. After this incubation the supernatant containing 
lamina propria cells was filtered and cells were washed in the same way as the intra-
epithelial cells. The intraepithelial and lamina propria population of cells were then 
pooled, centrifuged at 1200 rpm for 15 minutes, re-suspended in 30% Percoll (Amersham 
Biosciences, Uppsala, Sweden), and centrifuged for 20 minutes 1650 rpm at room 
temperature.  The top layer of cells, which contained epithelial cells, was discarded and 
the pellet was re-suspended in PBSA-buffer and centrifuged for 10 minutes, 800 rpm, at 
4˚C. The pellet was re-suspended in RPMI-supplemented, the cells were counted and 
plated in ELISPOT plates. 
 
3.3.9  Antigen-specific ASC assay 
Ag-specific antibody-secreting cells (ASC) were detected using a modified 
ELISPOT assay. 96 well nitrocellulose filtration plates (Whatman Inc, Clifton, NJ, USA) 
were coated overnight with either 50 µg/ ml of pure F4 fimbrial protein at 100 µl/well or 
500 µg/ ml of chicken egg Ovalbumin (OVA) (SIGMA, St. Louis, MO, USA) at 100 
µl/well . Wells were washed to remove free protein before adding 5×105 cells/well to 
triplicate wells, in a final volume of 200 ul culture medium. Cultures were incubated for 
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18 h at 37 °C in a humidified atmosphere with 5% CO2 before removing the cells. ASC 
were detected by first adding mouse anti-porcine IgA (1:300 dilution; Cedarlane 
Laboratories, Hamilton ON, Canada) followed by phosphatase labeled goat anti-mouse 
IgG (H+L chain specific; 1:5000 dilution; Kirkegaard and Perry Laboratories, 
Gaithersburg, MD, USA) or phosphatase labeled goat anti-swine IgG (H+L chain 
specific; 1:5000 dilution; Kirkegaard and Perry Laboratories, Gaithersburg, MD, USA). 
ASC were visualized with 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium 
(BCIP/NBT) insoluble alkaline phosphatase substrate (Sigma-Aldrich). The frequency of 
F4-specific ASC per 5×106 cells was calculated by subtracting the number of ASC 
detected in wells not coated with Ag from the number of ASC detected in Ag-coated 
wells. An inverted light microscope was used to count three replicate wells for each cell 
population isolated from a given loop, and data presented are mean values of replicate 
samples. 
 
3.3.10  ELISA 
Polystyrene microtiter plates (Immunolon® II; Dynatech Laboratories, 
Gaithersburg, Maryland, USA) were coated with 50 µg/ml of pure F4 fimbrial protein 
and incubated with serum (1 in 40) dilution 4 fold diluted). Phosphatase labeled goat anti-
swine IgG (H+L chain specific; 1:5000 dilution; Kirkegaard and Perry Laboratories, 
Gaithersburg, MD, USA) was used to detect serum IgG, whereas mouse anti-porcine IgA 
(1:300 dilution; Cedarlane Laboratories, Hamilton ON, Canada) plus phosphatase labeled 
goat anti-mouse Ig (H+L chain specific; 1:5000 dilution; Kirkegaard and Perry 
Laboratories, Gaithersburg, MD, USA) were used to detect F4-specific IgA secreted into 
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the loops.  The reaction was visualized with p-nitrophenyl phosphate (PNPP; Sigma-
Aldrich). The titer equals the reciprocal of the highest dilution that gave a positive OD 
reading. A positive reading was defined as an OD that was at least two times greater than 
the values for a negative sample.  
 
3.3.11  Statistical analysis 
Individual loops were treated as a unit of analysis (n = 113). A regression analysis 
was performed to determine the relationship between F4R-expression and the number of 
either IgA-ASCs or IgG-ASCs. In order to increase statistical power, all F4-immunized 
loops were included into the analysis (total of F4-immunized loops: n = 77; total of 
control loops: n = 36). The effect of F4R-expression, F4 dose and the interaction of these 
two variables upon the number of ASCs were examined using ordinary least squares 
regression. The IgA-ASC and IgG-ASC data were not normally distributed and therefore 
the logarithm of each variable was used in the regression analysis. P values less than 0.05 
were considered significant.  
 
3.3.12  Experimental outline 
 Five experiments were performed (see Table 3.1) to address our objectives and 
hypothesis.  
Experiment 1, was performed to test the immunogenicity of our electroeluted 
purified F4 fimbrial protein in surgically created pig gut-loops in 3-week old pigs. OVA 
was injected into loops as a positive control, PBSA loops were our negative control loops  
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Experiment 2, was used to test the immunogenicity of the crude form of the F4 
protein in surgically created pig gut-loops in 3-week old pigs. OVA was injected into 
loops as a positive control, PBSA loops were our negative control loops  
Experiment 3 was a dose titration trial to determine the effect of dose on the F4-
specific immune response in pig gut-loops in 3-week old pigs. PBSA loops were used as 
a negative control.   
Experiments 4 and 5 tested our hypothesis that an adjuvant effect could be 
obtained by co injecting either CpG ODN 2007 or pBD-1 with crude F4 fimbrial protein 
into the gut-loops of 3-week-old pigs. The surgical maps of all gut-loop experiments are 
shown in (Figure 3.3) 
Table 3.1.  The experimental design for all five gut loop experiments that lists the 
number of pigs/trial, the concentration of F4 Ag, OVA, and adjuvant. The number 
of immunized and non-immunized loops are also shown.    
                                                       
Exp # of 
Pigs 
Dose of  F4 
(µg/loop) 
Dose  of 
OVA(µg/loop) 
 
                   
# of  loops 
immunized 
 
# of control loops 
immunized 
1 4 500 500 4       2 
      
2 4 500 500 4       2 
      
3 5 50, 250, 500  6       2 
      
Exp  # of 
Pigs 
Dose of F4 
(µg/loop) 
Dose  of CpG    
(µg/loop) 
 
                   
# of  loops 
immunized 
# of Control loops
immunized 
4 6 125 500 6       2 
      
Exp  # of 
Pigs 
Dose of F4 
(µg/loop) 
Dose of pBD-1   
(µg/loop) 
 
                   
# of loops 
immunized 
# of Control loops 
immunized 
5 7 125 500 6       2 
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Figure 3.3.  Surgical maps: (A) and (B) tested the immunogenicity of the F4; (C) and (D) tested adjuvants CpG ODN and pBD-1.    
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3.4 Results 
 
3.4.1  Purification of F4ac fimbriae using electro-elution 
To obtain pure F4 protein, SDS-PAGE gels were loaded with crude F4 protein 
and afterwards a single band of 26kDa in size was electroeluted and named pure F4 
protein. Purity was confirmed by SDS PAGE gel (Figure. 3.4 (A)) and was recognized by 
an F4-specific rabbit polyclonal antibody in our Western blot (Figure. 3.4 (B)). The 
electroelution process yielded approximately 2.5 mg of pure F4 fimbrial protein from 4 
liters of ETEC F4 liquid culture. In contrast the mechanical shearing method used to 
obtain crude F4 protein yielded approximately 8-10 mg of F4 protein from 1 liter of 
ETEC F4 liquid culture. 
 
3.4.2  Inhibition of ETEC F4ac to F4-specific brush border receptors by F4ac 
fimbrial protein 
The use of mechanically sheared F4ac fimbriae to block the adhesion of ETEC 
F4ac to F4-specific brush border receptors of an F4Rpos pig was tested against four 
different concentrations of F4ac protein at 2, 10, 20 and 50 µg (Figure 3.5). As the 
amount of F4 protein was increased from 2 to 50 µg the number of ETEC F4 adhering to 
villous brush border receptors decreased. The IVVA was used to measure the inhibition 
effect of the F4 protein on ETEC F4 binding to F4Rpos villi.  
No inhibition was seen when  0, 2, and 10 µgs of  F4 protein were used as their 
mean  adherence values were 32 ± 12,  31 ± 7, and 40 ± 11, coliforms binding / 250 µm 
of villous brush border respectively. Conversely at 20 and 50 µgs of F4 a marked decline 
in adherence was seen as evidenced by mean adherence values of 6 ± 2, and 0 ± 0, ETEC 
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F4 binding / 250 µm of villous brush border respectively. Thus a statistically significant 
effect was seen for F4 fimbriae to inhibit the adherence of ETEC F4 to F4Rpos villi 
(P<0.0001; r2= 57%) as the inhibition rose from 0% at 10 µg of F4ac protein, to 100% for 
50 µg of F4ac fimbriae used.  
   A                                                                    B 
                                  
 
Figure 3.4  SDS PAGE and Western blot were used to demonstrate the purity of the F4 
protein (26kD). The F4 fimbrial protein which was purified by SDS PAGE and 
electroelution is shown on an SDS PAGE gel (A); along with a non-fimbriated E.coli 
strain (EL14) that was processed by centrifugation, shearing, ammonium sulphate 
precipitation, and overnight dialysis in ultra-pure H20. Five micrograms of protein was 
loaded per well; lane 1 marker; lane 2 pure F4; lane 3 EL14; lane 4 ovalbumin (OVA). 
The identification of F4ac fimbriae in a Western Blot (B); lane 1 marker; lane 2 pure F4; 
lane 3 EL14; lane 4 ovalbumin (OVA), a polyclonal serum derived from F4 crude-
immunized rabbits was used for detecting the purified F4 fimbriae.  
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Figure 3.5  The inhibition of adherence of ETEC F4 binding to villi of an F4Rpos pig by 
pre-incubating the villi with various concentrations of F4ac crude fimbrial protein (2, 10, 
and 20, 50 µgs/ml) obtained by the shearing method. No inhibition of adherence of ETEC 
F4 binding to villi of an F4Rpos pig was seen when F4ac crude fimbrial protein was 
omitted in the pre-incubation step.   
  
 
3.4.3  Use of rPAb to inhibit binding of ETEC F4ac to F4-specific brush 
border receptors  
The use of rPAb to block the adhesion of ETEC F4 to F4-specific brush border 
receptors of an F4Rpos pig was tested against the following volumes of F4-specific rPAb 
2, 5, 10, and 20 µls (Figure 3.6). As the amount of rPAb increased from 2 to 20 µl the 
number of ETEC F4 adhering to villous brush border receptors decreased. The IVVA was 
used to measure the inhibition effect of rPAb on ETEC F4 binding to F4Rpos villi.  
There was a statistically significant effect of the rPAb to inhibit the binding of ETEC F4 
to F4Rpos villi (P<0.0001; r2= 83%). Villi that were pre-incubated with 2 and 20 µl  of  
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F4-specific rPAb had a mean adherence of 44 ± 9.3 (0% inhibition) and 3.0 ± 2.9 (93 % 
inhibition) coliforms binding / 250 µm of villous brush border respectively compared to a 
mean of 42 ± 4.4 adherent ETEC F4 / 250 um of villi when no F4-specific rPAb was 
used. Conversely there was no inhibition effect upon the adherence when preimmune 
rPAb was used (P=0.76; r2= 0.05%). Villi that were pre-incubated with 2 and 20 µl rPAb 
had a mean adherence of 39.3 ± 11.7 and 44.5 ± 9.9 respectively.   
 
3.4.4  Use of mMAb to inhibit binding of ETEC F4ac to F4-specific brush 
border receptors  
The use of mMAb to block the adhesion of ETEC F4 to F4-specific brush border 
receptors of an F4Rpos pig was tested against four different volumes of F4-specific 
mMAb 2, 5, 10, and 20 µls (Figure 3.7). As the amount of mMAb increased from 2 to 20 
µl the number of ETEC F4 adhering to villous brush border receptors decreased. The 
IVVA was used to measure the inhibition effect of mMAb on ETEC F4 binding to F4Rpos 
villi.  
There was a statistically significant effect of the mMAb to inhibit the binding of 
ETEC F4 to F4Rpos villi (P<0.0007; r2= 46%). Villi that were pre-incubated with 2 and 20 
µl of F4-specific mMAb had a mean adherence of 44.5 ± 4.9 (0% inhibition) and 5.0 ± 
7.6 (87.5 % inhibition) coliforms binding / 250 µm of villous brush border respectively 
compared to a mean of 40.25 ± 20.7 adherent ETEC F4 / 250 um of villi when no F4-
specific mMAb was used. Conversely there was no inhibition effect upon the adherence 
when mIAb serum was used (P=0.82; r2= 0.05%). Villi that were pre-incubated with 2 
and 20 µl mIAb had mean adherence values of 42.5 ± 8.7 and 39.0 ± 10.7 respectively.   
  44
 
Figure 3.6  A: The inhibition of adherence of ETEC F4 binding to villi of an F4Rpos pig 
by pre-incubating the villi with various concentrations of F4ac-specific rabbit polyclonal 
antibody (rPAb) B: No inhibition of adherence of ETEC F4 binding to villi of an F4Rpos 
pig by pre-incubating the villi with various concentrations of an rabbit polyclonal 
antibody (rPAb) (used as a control). 
 
 
Figure 3.7  A: The inhibition of adherence of ETEC F4 binding to villi of an F4Rpos pig 
by pre-incubating the villi with various concentrations of  F4ac-specific mouse 
monoclonal antibody (mMAb) B: No inhibition of adherence of ETEC F4 binding to villi 
of an F4Rpos pig by pre-incubating the villi with various concentrations of an irrelevant 
mouse polyclonal antibody (mIAb) (Mouse IgG1-specific) used as a control. 
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 3.4.5  Induction of local intestinal immune responses against pure F4 
fimbriae 
Local immune responses against the electroeluted F4 fimbriae were assessed after 
24 days by quantifying the number of IgA- and IgG-ASCs in PPs for each of the loops 
containing 250 and 500 ug of pure F4 protein. A detailed outline of the experimental 
design is given in table 3.2. No F4-specific ASCs were found in loops immunized with 
the pure F4 protein. Further, no F4-specific immune responses were found in PPs from 
PBSA-treated and OVA-immunized loops. OVA specific IgA- and IgG-ASCs were not 
elicited in OVA immunized loops neither.  
 
3.4.6 Induction of local intestinal immune responses against crude F4 
fimbrial protein.  
Local immune responses against crude F4 fimbrial protein were assessed after 24 
days by quantifying the number of IgA- and IgG-ASCs in PPs for each of the loops 
containing 500 ug of crude F4 protein. A detailed outline of the experimental design is 
given in table 3.2. Median values of 92 IgA-ASCs/ 5 x 106 cells (min. 6 – max. 274) and 
55 IgG-ASC/ 5 x 106 cells (min. 3 – max. 216) isolated from PP were found (Figure 3.8). 
In contrast, no F4-specific ASCs were found in PPs from PBSA-treated and OVA-
immunized loops. However, OVA specific IgA- and IgG-ASCs were found in loops 
immunized with 500 µg of OVA. Median values of 122 IgA-ASCs/ 5 x 106 cells (min. 10 
– max. 308) and 58 IgG-ASCs/ 5 x 106 (min. 0 – max. 169) cells isolated from PP were 
found (Table 3.2). 
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A                                                           B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8  Number of F4-specific IgA-ASCs (A) and IgG-ASCs (B) in PPs from loops 
immunized with crude F4 protein. The number of F4-specific IgA- and IgG-ASC is 
shown. Each IgA- and IgG-ASC value is the mean ± the standard deviation (SD) of a 
triplicate of wells each receiving 100 µl of 5 x 106 isolated follicular PP cells/ml. The 
F4R statuses of the pigs were 180+++, 181++, 182+, and 183+++. Pig #-c represents the 
number of F4-specific Ig-ASCs in control loops; Pig #-F4 represents the number of F4-
specific Ig-ASCs in F4-immunized loops. 
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Table  3.2 Number of F4- a5nd OVA-specific ASC in F4- and OVA-immunized loops. Non-immunized loops (not shown) had no F4-
specific ASCs. F4Rhigh (+++), F4Rmedium (++), F4Rlow (+), F4R- neg. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exp Pig F4 
µg/loop  
F4-ASC in immunized loops  
 
OVA 
µg/loop 
F4-ASC in OVA- immunized loops 
 
     IgA  IgG  IgA IgG 
1  74++ 500 0 ± 0; 0 ± 0 0 ± 0; 0 ± 0 500 0 ± 0; 0 ± 0 0 ± 0; 0 ± 0 
  75+++ 500 0 ± 0; 0 ± 0 0 ± 0; 0 ± 0 500 0 ± 0; 0 ± 0 0 ± 0; 0 ± 0 
  76- 500 0 ± 0; 0 ± 0 0 ± 0; 0 ± 0 500 0 ± 0; 0 ± 0 0 ± 0; 0 ± 0 
  77++ 500 0 ± 0; 0 ± 0 0 ± 0; 0 ± 0 500 0 ± 0; 0 ± 0 0 ± 0; 0 ± 0 
        
2 180+++ 500 53 ± 16; 41 ± 8 84 ± 16; 123 ± 18 500 62 ± 1; 99±28  101 ± 26; 75 ± 5 
 181++ 500 10 ± 3; 6 ± 2 18 ± 6; 26 ± 1 500 10± 2; 12 ±1   0 ± 0; 0 ± 0 
 182+ 500 141 ±11; 130 ± 21 9 ± 7; 3 ± 3 500 307±39; 308 ± 57  17± 6; 22 ± 0 
 
 
183+++ 500 274 ± 15; 231 ± 33 216 ± 21; 176 ± 25 500 83 ± 4; 110 ± 12  169 ± 24; 82 ± 19 
47
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3.4.7 Immunization with varying doses of crude F4 protein 
Five pigs were immunized with 50, 250 or 500 µg crude F4 protein in gut-loops 
and the number of F4-specific ASCs from the PPs were enumerated. A detailed outline of 
the experimental design is given in table 3.3. No F4-specific immune response was seen 
in the F4Rneg pig at any dose. In contrast, the F4Rlow pig displayed between 1- 32 F4-
specific IgA ASC/ 5 x 106 cells and 5 - 43 F4-specific IgG-ASC/ 5 x 106 PP cells (Figure 
3.9 (B) and (D)). Between 6 - 146 F4-specific IgA-ASC/ 5 x 106 cells and 5 - 236 F4-
specific IgG-ASC/ 5 x 106 cells were found in F4Rhigh pigs depending on the dose used 
for immunization (Figure 3.9 (A-D)). With the exception of two loops in one animal, no 
F4-specific ASCs were found in PBSA-treated control loops (IgA-ASC: min. 0 – max. 4; 
IgG-ASC: min. 0 – max. 42). Due to the low number of pigs used in this dose experiment 
we felt that an analysis of all the loops from the four successful gut-loop experiments in 
which doses of 50, 125, 250 and 500 µgs of F4/loop were used would be more powerful 
in terms of statistical relevance regarding the dose effect. Therefore, the data obtained 
from all these experiments was subject to a least squares linear regression analysis to 
study the effect of dose, the expression level of the F4R, and level of maternal antibodies 
present in the serum, on the magnitude of the F4-specific log-IgA and IgG-ASC immune 
response (see appendix).  
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A                                                             B 
 
                                                                                       
 
 
 
 
 
 
 
 
C                                                              D 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9  The effect of dose on the local F4-specific immune response against crude F4 
fimbrial protein in pig gut-loops. Control loops were administered 1 ml of PBSA (not 
shown), and the immunized loops contained 500, 250 and 50 ug/ml of crude F4 fimbrial 
protein. (A) and (B) show the F4-specific IgA-ASC immune response, (C) and (D) the 
F4-specific IgG-ASC immune response in the loops from pigs 217, 218, 220, 221, and 
222; Each IgA-ASC value is the mean ± the standard deviation (SD) of a triplicate of 
wells each receiving 100 µl of 5 x 106 isolated follicular PP cells/ml. The F4R statuses of 
the pigs were 217neg, 218+++, 220+++, 221+++, 222+. 
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Table 3.3.  Number of F4-specific ASC in F4-immunized and non-immunized control 
loops. F4Rhigh (+++), F4Rmedium (++), F4Rlow (+), F4R- neg. 
 
 
Exp 
 
  Pig    F4 µg/loop  F4-ASC in 
 immunized loops  
 
F4-ASC in  
non-immunized loops 
(PBSA) 
   
3
     
 IgA  IgG IgA IgG 
   217-        50 0 ± 0 
0 ± 0 
0 ± 0  
0 ± 0 
0 ± 0  
 
0 ± 0 
 
           250 0 ± 0 
0 ± 0 
0 ± 0  
0 ± 0 
0 ± 0  
 
0 ± 0 
 
         500 0 ± 0 
0 ± 0 
0 ± 0  
0 ± 0 
0 ± 0  
 
0 ± 0 
 
 218+++        50 31 ± 7  
8 ± 5 
236 ± 9 
118 ± 54 
0 ± 0 
0 ± 0 
42± 6  
11 ± 3 
  250 138 ± 13  
118 ± 28 
125 ± 17 
77 ± 19 
  
  500 145 ± 11  
70 ± 13 
180 ± 19  
42 ± 7 
  
 220+++        50 6 ± 1  
9 ± 1 
15 ± 6 
33 ± 1 
0 ± 0  
0 ± 0 
0 ± 0 
0 ± 0 
   250 55 ± 14   
14 ± 3 
47 ± 10  
21 ± 8 
  
  500 106 ± 20  
29 ± 4 
110 ± 19  
49 ± 2 
  
 221+++        50 64 ± 4  
16 ± 2 
20 ± 2  
5 ± 2 
0 ± 0  
0 ± 0 
0 ± 0  
0 ± 0 
  250 50 ± 4  
115 ± 14 
20 ± 7 
 40 ± 7 
  
  500 58 ± 8  
146 ± 7 
21 ± 1  
42 ± 8 
  
  222+       50 13 ± 6  
18 ± 7 
10 ± 3  
11 ± 2 
0 ± 0 
0 ± 0 
0 ± 0  
0 ± 0 
        250 32 ± 8 
 3 ± 1  
43 ± 11 
 10±2 
  
        500 1 ±1  
14 ± 1 
5 ± 3  
17 ± 2 
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3.4.8  The adjuvant CpG ODN did not enhance the local F4-specific immune 
response in loops when coadminstered with crude F4 protein  
From our dose experiment, we determined that immunizing with either 250 µg or 
500 µg crude F4 protein on average induced higher F4-specific ASC-immune responses 
in the loops of F4Rpos pigs than immunization with the dose of 125 µg F4/loop. Therefore 
125 µg F4/loop was chosen to be co administered with CpG ODN so that the effect of 
adjuvant could be detected. A detailed outline of the experimental design is given in table 
3.4. Three loops in six pigs were immunized with 125 µg F4 or 125 µg F4 plus 500 µg 
CpG ODN 2007 (sequence TCG TCG TTG TCG TTT TGT CGT T) per loop. Two loops 
per animal were treated with PBSA. Two of the pigs were F4Rneg, and the remaining four 
pigs were F4Rlow to F4Rmod.  
The mean values of 15 F4-specific IgA-ASC (min. 1 – max. 116) and 20 IgG-
ASC/ 5 x 106 cells (min. 1 – max. 251) were found in F4-immunized loops (Figure 3.10 
(A)-(F)). In contrast mean values of 10 F4-specific IgA-ASC (min. 1- max. 53) and 17 
IgG-ASC/ 5 x 106 cells (min. 1 – max. 333) were found in F4-CpG immunized loops 
(Figure 3.10 (A)-(F)). Interestingly, in F4Rneg animals very low to moderate numbers of 
F4-specific ASCs were detected in immunized loops. Very low numbers of F4-specific 
IgA-ASC/ 5 x 106 cells (min. 1 – max. 17) and IgG-ASCs/ 5 x 106 cells (min. 1 – max. 4) 
were detected in control loops. Thus, no significant differences were seen in the number 
of F4-specific ASCs in loops immunized with crude F4 protein versus crude F4 protein 
plus CpG ODN.   
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  A                                                                      B 
 
 
 
 
 
  C                                                                       D                    
 
 
 
 
 
 
 
 
 
 
 
   E                                                                       F 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10  The number of F4-specific IgA- and IgG-ASC isolated from the PPs of gut- 
loops from pigs 429 (A), 430 (B), 433 (C), 434 (D), 437 (E) and 438 (F) are shown 
above. Control loops were administered 1 ml of PBSA, F4 immunized loops contained 
125 µg crude F4 protein, and CpG immunized loops contained 125 µg of crude F4 
protein + 500 µg CpG ODN 2007. Each IgA- and IgG-ASC value is the mean ± the 
standard deviation (SD) of a triplicate of wells each receiving 100 µl of 5 x 106 isolated 
follicular PP cells/ml. The F4R statuses of the pigs were 434neg, 429++, 430++, and 433++, 
437-, 438+. 
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Table 3.4  Effect of CpG ODN 2007 on the induction of F4-specific antibody secreting cells in the gut.  F4Rhigh (+++), F4Rmedium (++), 
F4R low (+)  F4Rneg (-). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Footnote:  * - only one control loop. 
 
   Exp 
     
     4 
Pig     F4 
µg/loop 
F4-ASC in 
immunized loops  
 
F4 + 
CpG 
µg/loop 
F4-ASC in  
F4-CpG ODN 
immunized loops 
 
 F4-ASC in     
control loops 
         IgA IgG  IgA 
 
IgG 
 
IgA IgG 
    
  429++ 
 
125 
15 ± 3 
 8 ± 3 
 6 ± 1 
32 ± 5 
11 ± 3 
18 ± 5 
 
125+500 
 6 ± 3       
11± 2 
 5 ± 1 
10 ± 2 
24± 6 
 4 ± 1 
2 ± 1 
0 ± 0 
 
1 ± 1 
0 ± 0 
 
  
  430++ 
 
125 
7 ± 1 
20 ± 3 
11 ± 2 
144 ± 6 
251 ± 19 
102 ± 6 
 
125+500 
22 ± 2 
11 ± 4 
13 ± 1 
332 ± 16 
146 ± 21 
69 ± 11 
1 ± 1 
0 ± 0 
 
4 ± 0 
0 ± 0 
  
  433++ 
 
125 
25 ± 7 
27 ± 9 
45 ± 5 
60 ± 9 
54 ± 8 
34 ± 8 
 
125+500 
23 ± 9 
41 ± 7 
53 ± 5 
120 ± 23 
33 ± 3 
57 ± 12 
0 ± 0 
0 ± 0 
0 ± 0 
0 ± 0 
 
  
  434- 
 
125 
1 ± 1 
1 ± 1 
9 ± 2 
14 ± 8 
 0 ± 0 
 0± 0 
 
125+500 
22 ± 1 
 0 ± 0 
 9 ± 2 
30 ± 3 
 9 ± 3 
 0 ± 0 
0 ± 0 
0 ± 0 
0 ± 0 
0 ± 0 
  
  437- 
 
125 
28 ± 2 
18 ± 4 
11 ± 0 
38 ± 2 
12 ± 4 
28 ± 3 
 
125+500 
23 ± 3 
1 ± 1 
3 ± 3 
27 ± 6 
1 ± 0 
0 ± 0 
0 ± 0 
0 ± 0 
0 ± 0 
1 ± 1 
  
 438+ 
 
125 
0 ± 0  
0 ± 0 
4 ± 3 
0 ± 0 
0 ± 0 
 
125+500 
N/A 
0 ± 0 
0 ± 0 
6 ± 1 
1 ± 1 
2 ± 1 
0 ± 0 
0 ± 0 
0 ± 0 
* 
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3.4.9  The adjuvant pBD-1 did not enhance the local F4-specific immune 
response in loops when coadminstered with crude F4 protein 
To test the effect of the pBD-1, three loops/pig in seven pigs were immunized 
with either 125 µg F4/loop or a combination of 125 µg F4/loop + 500 µg pBD-1/loop. 
Two control loops were injected with PBSA. Two of the pigs were F4Rneg, four were 
F4Rlow-mod and one was F4Rhigh. A moderate dose of the F4 (125 µg F4/loop) was chosen 
to be co administered with pBD-1 so that the effect of adjuvant could be detected. A 
detailed outline of the experimental design is given in table 3.5. The mean values of 15 
F4-specific IgA-ASC/ 5 x 106 cells (min. 1 to max 116) and 20 IgG-ASC/ 5 x 106 cells 
(min. 1 to max. 251) were found in F4-immunized loops and 17 F4-specific IgA-ASC 
(min. 1 to max 69) and 22 IgG-ASC/ 5 x 106 cells (min. 1 to max. 155) were found in F4-
pBD-1 immunized loops (Figures 3.11 and 3.12). F4Rneg animals again displayed low to 
moderate numbers of F4-specific ASCs. Thus, no significant differences were seen in the 
number of F4-specific ASCs in loops immunized with crude F4 protein versus crude F4 
protein plus pBD-1.   
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 A                                                                        B 
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Figure 3.11  The number of F4-specific IgA- and IgG-ASC isolated from the PPs of gut 
loops from pigs 439 (A), 489 (B), 491 (C), and 1 (D) are shown above. Control loops 
were administered 1 ml of PBSA, F4 immunized loops contained 125 µg crude F4 
protein, and pBD-1 immunized loops contained 125 µg of crude F4 protein + 250 µg 
porcine β defensin-1. Each IgA- and IgG-ASC value is the mean ± the standard deviation 
(SD) of a triplicate of wells each receiving 100 µl of 5 x 106 isolated follicular PP 
cells/ml. The F4R statuses of the pigs were 439neg, 489++, 491+++, and 1+.  
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Figure 3.12  The number of F4-specific IgA- and IgG-ASC isolated from the PPs of gut 
loops from pigs 2 (A), 3 (B), 4 (C) are shown above. Control loops were administered 1 
ml of PBSA, F4 immunized loops contained 125 µg crude F4 protein, and pBD-1 
immunized loops contained 125 µg of crude F4 protein + 250 µg porcine β defensin-1. 
Each IgA- and IgG-ASC value is the mean ± the standard deviation (SD) of a triplicate of 
wells each receiving 100 µl of 5 x 106 isolated follicular PP cells/ml. The F4R statuses of 
the pigs were 2neg, 3+, and 4++. 
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Table 3.5  Effect of pBD-1 on the induction of F4-specific antibody secreting cells in the gut.  F4Rhigh (+++), F4Rmedium (++), F4R low (+)  
F4Rneg (-). 
 
 
 
 
Exp Pig F4 
µg/loop 
F4-ASC in  
F4-immunized loops 
 
F4 + pBD-1 
µg/loop 
F4-ASC in  
F4-pBD-1  
immunized loops 
 
F4-ASC in 
control loops 
 
      5   IgA IgG  IgA IgG IgA IgG 
  
 439 - 
 
125 
16 ± 2 
 0 ± 0 
 6 ± 1 
38 ± 6  
2 ± 2  
0 ± 0 
  
  125+250 
6 ± 1 
 0 ± 0 
 0 ± 0 
22 ± 3  
0 ± 0 
0 ± 0 
0 ± 0 
0 ± 0 
 
2 ±0 
* 
  
489 ++ 
 
125 
22 ± 4 
*** 
     
53 ± 4 
***     
     
  
  125+250 
44 ± 2 
25 ±7 
 **     
39 ± 12 
27 ± 4 
    ** 
0 ± 0 
0 ± 0 
 
0 ±0 
* 
    
   
491+++ 
 
125 
68 ± 4 
89 ± 21 
52 ± 9 
25 ± 2 
47 ± 10 
23 ± 5 
  
  125+250 
68 ± 4 
52 ± 
13 
15 ± 6 
32 ± 5 
15 ± 2 
7 ± 1 
17 
±5* 
 
     
4 ±0*
 
   
    
   1 + 
 
125 
116 ± 
16 
93 ± 9 
56 ± 2 
115 ± 14
114 ± 10
 69 ± 6 
  
  125+250 
44 ± 7 
69 ± 
17 
26 ± 6 
42 ± 14 
57 ± 14 
 37 ± 4 
0 ± 0 
0 ± 0 
0 ± 0 
0 ± 0 
    
   2 - 
 
125 
21 ± 4 
13 ± 3 
6 ± 3 
20 ± 6 
5 ± 2 
4 ± 1 
  
  125+250 
4 ± 3 
1 ± 1 
1 ± 1 
6 ± 2 
2 ± 2 
1 ± 0 
0 ± 0 
0 ± 0 
0 ± 0 
0 ± 0 
    
   3 + 
 
125 
28 ± 9  
57 ± 19 
7 ± 1 
58 ± 24 
174 ± 21
15 ± 3 
 
  125+250 
23 ± 6 
22 ± 8 
17 ± 5 
31 ± 4 
64 ± 4 
46 ± 6 
0 ± 0 
0 ± 0 
1 ± 0 
0 ± 0 
    
   4 ++ 
 
125 
3 ± 1  
18 ± 4 
7 ± 3 
 3 ± 3 
 0 ± 0 
 N/A 
  
  125+250 
0 ± 0  
32 ± 6 
N/A 
0 ± 0 
155 ± 10 
N/A 
0 ± 0 
0 ± 0 
0 ± 0 
0 ± 0 
Footnote: * - only one control loop; N/A – not enough cells collected; ** - only one immunized loop was viable*** 
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3.4.10  Importance of the F4R for the local immune response 
To analyze the role of the F4R for the eliciting of the F4-specific immune 
response in our gut-loops we examined all loops from all pigs except those deemed 
secondary responders (cohorts 429, 430, and 491). Doses of 0, 50, 125, 250, and 500 
µg/ml were administered to loops and the expression level of the F4R as determined by 
the IVVA on the F4-specific immune response was measured by taking the log of the F4-
specific IgA or IgG ASCs isolated from loop PPs.  
There was a significant effect of  F4R expression upon the number of IgA-ASCs 
(P< 0.0001; r2 value= 41%) and IgG-ASC (P < 0.0001; r2 value= 0.36) (Figures 3.13 and 
3.14) (also see appendix for a more detailed analysis). Interestingly when the non-
immunized loops from all cohorts were removed from the data set a dose effect was not 
observed for neither the F4-specific IgA-ASCs (P=0.13) nor IgG-ASCs (P=0.87) 
responses (Figures 3.16 and 3.17) (also see appendix for a comprehensive analysis of 
loop data). Furthermore, increased doses of F4 Ag were not always associated with an 
upward shift in the dose response curve see Figures 3.16 and 3.17. Therefore, the 
statistical effect of dose was due to administering the crude F4 protein rather than 
increasing its dose. Thus, these results demonstrate that the level of F4R expression and 
the event of immunization were crucial for the induction of local immunity in the small 
intestine of pigs.  
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Figure 3.13  Using only the data from loops administered various doses of crude F4 
protein, only the expression level of the F4R (P < 0.0001) was significantly associated 
with the log of the IgA-ASC immune response. R-squared = 41%. Dose however was not 
associated with the log of the IgA-ASC immune response (P = 0.13). (50 µg    ,  
125 µg     ,250 µg      , and 500 µg     ). 
 
 
50 ? 
250 ? g 
125 ? 500 ? 
Dose of F4 
ug/loop 
 
50 
250
 
ug/loop
 
ug/loop
ug/loop
  60
 
 
 
 
 
Figure 3.14  Using only the data from loops administered various doses of crude F4 
protein, only the expression level of the F4R (P < 0.0001) was significantly associated 
with the log of the IgG-ASC immune response. R-squared = 36%. Dose however was not 
associated with the log of the IgG-ASC immune response (P = 0.87 (50 µg    , 125 µg     , 
250 µg    , and 500 µg     ). 
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3.4.11  F4Rpos and F4Rneg pigs grouped according to the number of F4-
specific ASCs in immunized loops versus F4-specific ASCs in non-immunized loops. 
F4Rpos pigs could be grouped according to the number of F4-specific ASCs in 
immunized loops versus F4-specific ASCs in non-immunized loops (Table 3.6). Eleven 
F4Rpos pigs had expected outcomes of vaccination as they displayed ≥ 10 F4-specific 
ASCs in immunized loops and no F4-specific ASCs in control loops. Two F4Rpos pigs 
had < 10 F4-specific ASCs in immunized loops and no F4-specific ASCs in control 
loops. The four remaining F4Rpos pigs had F4-specific ASCs in immunized loops and F4-
specific ASCs in control loops however two of these pigs had > 10 F4-specific ASCs in 
their control loops indicating that they may have been preexposed to ETEC F4 (2o 
responders) prior to immunization. Five F4Rneg pigs were also grouped according to their 
response to F4-immunization (Table 3.7). Three of these pigs had > 10 F4-specific ASCs 
in immunized loops and no F4-specific ASCs in their control loops, which indicates that 
F4Rneg pigs indeed respond to vaccination. Only one F4Rneg pig had no F4-specific ASC 
in both immunized and non-immunized loops.  
 
Table 3.6.  F4Rpos pigs were grouped based upon the number of F4-specific ASCs in 
immunized loops versus F4-specific ASCs in non-immunized loops. 
 
F4-ASC in immunized 
loops 
 
F4-ASC in control loops Number of animals 
≥ 10 
 
0 11 
< 10 
 
0 2 
≥ 10 
 
                  < 10 2 
> 10 
 
                  > 10 2 
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Table 3.7.  F4Rneg pigs were grouped based upon the number of F4-specific ASCs in 
immunized loops versus F4-specific ASCs in non-immunized loops.   
 
 
F4-ASC in immunized 
loops 
 
F4-ASC in control loops Number of animals 
≥ 10 
 
0 3 
< 10 
 
0 2 
≥ 10 
 
< 10 0 
> 10 
 
> 10 0 
 
 
3.4.12 F4-specific serum antibody response following intestinal immunization 
Serum samples were taken from all our pigs on the day of surgery and on day 
twenty-four and analyzed for the presence of F4-specific IgG immunoglobulin’s. Out of 
twenty-two pigs analyzed only five showed noteworthy increases in serum F4-specific 
titers after F4-immunization into our gut-loops (Table 3.8). This indicates that perhaps 
F4-immunization into our loops was not effective in eliciting systemic F4-specific IgG. 
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Table 3.8.  F4-specific serum antibody titers at the day of gut-loop surgery and at the 
time of tissue collection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Pig  Day 0 Day 24 
180 68 46 
181 795 480 
182 63 51.5 
183 52 103 
217 113 323 
218 58 61 
220 113 39.5 
221 51 16 
222 50 39 
429 95 41 
430 0 12 
433 35 36 
434 17 39 
437 104 82 
438 145 63 
439 159 64 
489 9 46 
491 15 20 
1 10 60 
2 47 14 
3 110 34 
4 75 28 
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3.4.13  The effect of F4-specific serum antibody on the F4-specific Ig-ASC 
response in the loops 
Interestingly, some pigs had higher F4-specific IgG antibody levels in their serum 
at day 0 (Table 3.8). This could be the result of prior exposure to ETEC F4 or perhaps 
passive transfer of maternal antibodies (mAbs) from the sow. Therefore, we decided to 
examine if F4-specific serum antibodies interfered with our gut-loop immunization by 
assessing the factors dose, the expression level of the F4R, and the F4-specific IgG titer 
at day 0. These variables were assessed in regression models with the log-transformed 
IgA- and IgG-ASCs in immunized loops as the outcome. Furthermore, pigs that we 
thought were 2o responders (220, 491, 430 and 431) were excluded from this analysis. 
Our results indicated that there was a statistical effect of the F4-specific serum IgG to 
inhibit the F4-specific IgA-ASC response in our gut-loops (P=0.004; for a detailed 
analysis see appendix). However this was not the case for IgG (P=0.08; for a detailed 
analysis see appendix).  
Thus, F4-specific IgG in the serum affected intestinal immunization with the 
native F4 protein in our loops. Further investigation is required to understand the 
mechanism of inhibition. 
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3.5  Discussion 
Protective vaccination against E. coli depends on the induction of local immune 
responses in the small intestine. Here, we show that vaccination with as little as 50 µg of 
purified F4/ loop resulted in the induction of local mucosal immune responses in 
immunized loops, but not in non-immunized control loops. Furthermore, we demonstrate 
that purified F4 induced weak immune responses in some F4Rneg animals. Interestingly, 
the induction of local immune responses was dependent on the level of F4R-expression 
within each loop: Whereas F4Rneg-low pigs mounted only weak immune responses in 
immunized loops, F4Rmod-high pigs mounted consistently higher F4-specific Ig ASC 
immune responses and displayed the most significant response to dose. Thus, expression 
of the F4R and binding of its ligand, the F4 protein, seemed critical for the induction of 
intestinal F4-specific immunity in our gut-loops.  
Uptake of F4 antigen across the mucosal surface can be mediated by either M 
cells that are located in the follicle-associated epithelium above PPs or by dendritic cells 
DCs that sample the antigen from the gut lumen. Both mechanisms are non-specific and 
theoretically could take place in both F4Rpos and F4Rneg animals. However, our results 
suggest that uptake of the F4 is more efficient in F4Rmod to high pigs as these animals 
mounted stronger immune responses against the F4. Thus, binding of the F4 to the F4R 
must result in an augmented uptake across the mucosal lining.  
M cells are specialized epithelial cells that preferably take up particulate antigen 
and it is most likely that binding of the F4 to the F4R would not alter this process. 
However, it is not known if porcine M cells express the F4R. In contrast, binding of the 
F4 to the F4R could significantly increase uptake by DCs. For example, the closer 
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proximity of the bound antigen could allow for a more efficient sampling by DCs as 
dendrites would be able to reach more of the antigen. Alternatively, binding to the F4R 
could also result in internalization of the F4 by epithelial cells, which would then pass the 
F4 onto DCs that are located underneath the epithelial layer. Both mechanisms favor the 
role of DCs and indicate that uptake and subsequent immune presentation by DCs 
represents the major pathway for the induction of F4-specific immunity in the intestine.  
Support for this hypothesis comes from the present data, which shows that F4Rneg 
and F4Rlow pigs only mount weak responses against F4 and from observations made by 
Van den Broeck et al., 1999 who first showed that immune responses were not detectable 
in orally immunized F4Rneg pigs. However, the same authors also reported that F4Rneg 
pigs had secondary responses following systemic booster immunization with F4, which 
indicated that priming had taken place in these animals 12. Thus, we conclude that 
immunity against the F4 can be induced in F4Rneg pigs. However, responses are very 
weak and often below the level of detection, which would explain the non-responsiveness 
to the primary immunization described by Van den Broeck et al., 1999. In the present 
study, we have used a gut-loop model, which allows a more controlled antigen delivery 
and much more detailed analysis of local immunity in the small intestine. Administration 
of F4 into surgically ligated loops and subsequent isolation of F4-specific cells 
specifically from these sites of immunization could provide a much higher level of 
sensitivity for detecting even weak immune responses and therefore could explain why in 
some F4Rneg animals F4-specific immune responses were found even after a primary 
immunization. However, more studies are required for a comprehensive understanding of 
the induction of mucosal immunity in F4Rneg pigs. 
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DCs are found along the mucosal surfaces of the intestine in several species 
including pigs 21. Uptake of bacterial antigens from the intestinal lumen was first 
described in mice by Rescigno et al., (2001) and further explored by others 22. Several 
subpopulations of DCs have been described in mice that can take up soluble antigen from 
the gut-lumen. These cells subsequently migrate towards the follicular zones and follicles 
within PPs or mesenteric LNs, where they can present the antigen to the immune system 
23. Although the existence of these DC subpopulations has not been confirmed in pigs, it 
is likely that DCs with similar functions exist in swine. Currently however, their exact 
location and proximity to the PP needs to be determined.  
Furthermore, evidence for the importance of DCs in the induction of F4-specific 
immune responses in the small intestine comes from studies in our lab, which 
demonstrated that F4-specific immune responses can be induced in interspaces, which are 
loops that lack PPs as major inductive sites 24. Thus, DCs play an important role in uptake 
of the F4 Ag and induction of F4-specific immune responses in the gut. Since F4-specific 
ASCs were found in both the PP and the mesenteric LN (data not shown), one can 
assume that DCs after uptake of the F4 Ag migrate towards the PP or directly towards the 
mesenteric LN to prime effector cells within the interfollicular and follicular regions 
respectively. Currently experiments in our lab are underway to analyze sampling of the 
F4 Ag by intestinal DCs, and ways to exploit the F4 Ag-F4R interaction to improve 
vaccines. 
Interestingly, in the present study we tried to improve upon the F4 Ags 
immunogenicity by using adjuvants i.e. CpG ODN, to enhance the number of F4-specific 
ASCs within immunized loops. In the past, several groups using a variety of species 
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including pigs have demonstrated the adjuvanting activity of CpG ODN. For example, 
systemic administration of CpG ODN to pigs enhanced immune responses against F4 and 
the Actinobacillus pleuropneumoniae outer membrane protein (OmlA) 8, 25. However, 
CpG ODN was only administered systemically in these studies. The potential of CpG 
ODN to function as mucosal adjuvant was reviewed by McCluskie et al., (2000) 26. In our 
pig gut-loops, we chose ODN 2007, a member of the B-class ODN, which are known to 
enhance B cell responses and therefore are considered the most effective adjuvanting type 
of CpG ODN. In addition, the immunostimulatory activity of ODN 2007 had been 
previously demonstrated in pigs 27, 28. Further, the dose of 500 µg / loop derived from gut-
loop studies in sheep, demonstrated that 500 µg CpG ODN / loop was most effective in 
adjuvanting immune responses against intestinally administered porcine serum albumin 
29. In contrast to these observations, however, combination with CpG ODN 2007 did not 
enhance the local immune response against F4 in our present study. Several factors such 
as insufficient CpG ODN dosing, inadequate formulation, and the time point of 
assessment could represent possible reasons for this failure. Clearly, more studies with 
larger number of animals are required to identify optimal efficacy of CpG ODN for 
intestinal immunization with F4. 
Similarly, this was also the case for the pBD-1, which was included in the present 
study because of its immunomodulatory activity in vitro and in vivo 30. Defensins have 
been described as potent immunomodulators that can modify immune responses against 
bacterial, viral and tumor antigens. However, very little information is currently available 
about stability and formulation, as well as optimal dosing and administration of these 
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compounds. Thus, further experiments are necessary to identify the potential of these 
immunomodulators for future vaccines. 
Vaccination against ETEC in both human and animals is complicated by a 
number of factors including interference with maternally-derived antibodies. Our results 
indicated that higher F4-specific antibody levels at the time of immunization interfered 
with the induction of mucosal immune responses in immunized loops. This is a well 
established concept, and in fact represents one of the biggest challenges in vaccinating 
the newborn infant or animal. Thus, more effective vaccines are required that can 
overcome this interference and indeed the pig provides a very useful model for 
understanding mucosal immunity against ETEC. The pig model could also be of 
relevance for enhancing our understanding of E.coli infections causing diarrhea in other 
species. For example, receptors for colony forming antigen (CFA) homologous to the 
F4R are found in humans making our results relevant for important diseases such as 
Traveler’s diarrhea. Moreover, our results demonstrate that these antigen-specific 
receptors in fact play an essential role for the induction of immunity against ETEC and 
demonstrate that uptake via M cells is not necessary for the induction of local immunity. 
This is an important finding since it is commonly believed that M cell uptake and 
induction of immunity within the Peyer’s patch are essential for the induction of mucosal 
immunity in the small intestine. Furthermore, these findings also have implications for 
the development of novel vaccine strategies against ETEC in both animals and humans as 
it may be possible to target antigen-specific receptors on mucosal epithelial cells to 
increase vaccine efficacy. Nevertheless, more studies are necessary to understand the 
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induction of mucosal immunity against E. coli and develop effective vaccines for both 
human and animals. 
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5.  DISCUSSION 
 
Our study demonstrated that a local F4-specific immune response was seen in the 
gut-loops of pigs immunized with the F4 Ag. The strength of the F4-specific immune 
response depended upon the expression level of the F4R. The effect of dose on the F4-
specific immune response seen in the loops was statistically insignificant when the dose 
of 0 (saline control) was removed from the analysis. The level of serum antibodies found 
in the weaned pig had a negative effect on the magnitude of the F4-specific immune 
response in the loops. Unfortunately, the F4-specific immune response in the loops was 
not enhanced using the adjuvants CpG ODN or the defensin pBD-1.  
The idea that the F4R is required to elicit an F4-specific immune response against 
the F4 Ag is not new. For over 30 years it has been known that F4Rneg pigs as apposed to 
F4Rpos pigs, would not get sick when infected with ETEC F4 thus establishing a genetic 
basis regarding the resistance and susceptibility for this disease 23. Moreover, we know 
that proteins like fimbria, lectins, and viral hemagglutinins, which have cognate receptors 
on animal membranes, elicit much more potent immune responses when delivered orally 
to animals than proteins that do not possess similar binding activities 141. Van den Broeck 
et al., 1999 reconfirmed this by vaccinating pigs with crude F4 protein demonstrating that 
this lectin like protein elicits F4-specific immunity in the small intestine.  
Similarly our group using intestinal loops in pigs also tested the immunogenicity 
of the crude F4 fimbrial protein and found that it was immunogenic in our gut-loops.
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 However, in order to demonstrate that the crude F4 protein was responsible for 
the F4-specific immune response, we isolated the F4 on an SDS PAGE gel and verified 
its presence by Western blot with an F4-specific rabbit polyclonal antibody. Moreover, 
we showed that the crude F4 protein is specific for the F4R through inhibiting the 
adherence of ETEC F4 in a series of modified IVVAs. For example, we pre-incubated 
ETEC F4 with crude F4 fimbrial protein, mMAb, or rPAb, prior to co-incubation with 
F4Rpos villi. All of these inhibitors worked to block the binding of ETEC F4 to F4Rpos 
villi in a dose dependant manner. Thus our inhibition assays demonstrated that our crude 
F4 fimbrial protein is specific for the F4R in the small intestine of pigs.   
  Interestingly, we found that an electroeluted version of the F4 protein did not 
elicit F4-specific Ig-ASCs in our first gut-loop experiment. This was likely due to its 
failure to reassemble into a form that was capable of binding the F4R, since the 
denaturing gel used in the purification process removed the minor subunits which are 
required in the bacteria for correct assembly of the nascent fimbriae 20. However since 
OVA did not elicit OVA-specific Ig-ASCs in OVA immunized loops, the possibility 
exists that the negative results we obtained were due to technical problems. Therefore due 
to the high cost of each gut-loop trial it was decided that we would use the crude form of 
the F4 fimbrial protein for all future experiments. Indeed in subsequent trials 
investigating the crude F4 Ag, it elicited F4-specific immune responses in the loops of 
both F4Rpos and F4Rneg pigs. 
The detection of F4-specific immune responses in F4Rneg pigs after immunization 
with solubulized F4 protein in our gut-loops was unexpected. This is because Van den 
Broeck et al., 1999 after orally administering crude F4 protein to weaned pigs indicated 
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that no F4-specific immune responses were seen in F4Rneg pigs but only a priming was 
detected. Thus our model in contrast to oral vaccination, allowed for the delivery of 
relatively large amounts of F4 Ag to a confined space (the loop) permitting us to 
immunize and look for F4-specific immune responses at the site of immunization. Thus 
our gut-loops permitted us to detect the on average of < 10 F4-specific ASC / 5 x 106 
cells typically present in the PPs of F4Rneg pigs.  
On the other hand, nominal F4-specific immune responses like the ones detected 
in the gut-loops of our F4Rneg pigs likely go unnoticed in oral immunization protocols 
because of the methods used to detect them. For example, fecal samples are typically 
collected and probed for F4-specific SIgA. However this method likely is not sensitive 
enough to detect the low numbers of F4-specific SIgA present in the feces of these pigs. 
Another method used to detect the F4-specific intestinal immune response to F4 oral 
immunization is the isolation of PBMCs from the blood. However, given the low number 
of F4-specific ASCs typically found in F4Rneg pigs there may not be enough F4-specific 
monomorphonuclear cells circulating in the blood to be detected 43. Thus, our gut-loop 
immunization protocol allowed us to detect the nominal F4-specific immune responses 
seen in F4Rneg pigs because we isolated F4-specific Ig-ASCs directly from PPs of loops 
that were immunized with the F4 protein.  
Interestingly, our gut-loop immunization did not elicit strong F4-specific IgG 
immune responses in the systemic immune compartment of F4Rneg or F4Rpos pigs.    
Evidence for this could be inferred from the fact that we were unable to isolate F4-
specific IgG-ASCs from the mesenteric lymph nodes in a majority of the pigs perhaps 
due to their frequency being to low. Moreover weak F4-specific immune responses in the 
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systemic immune compartment could have been masked by waning levels of maternal 
antibodies. Therefore until we modify our ELISA to detect either sow (IgG2A) or piglet 
IgG (IgG1) in the serum we can not conclude if F4-loop immunization elicits F4-specific 
immune responses in the serum.   
Interestingly, a statistical analysis of the pre-immune serum IgG revealed that it 
was inhibitory upon the F4-specific IgA-ASC response seen in the loops after 
immunization with the F4. A potential reason for this is that maternal immunoglobulins 
still present in the mucus layer of the small intestine of the weaned pig could be 
inhibiting the binding of the F4 Ag to the F4R preventing uptake and subsequent 
induction of the F4-specific immune response. Thus, it appears that passive immunity 
transferred by the sow to the piglet during the suckling period can influence the outcome 
of F4-immunization in our loops. Therefore in future pig gut-loop trials we can prescreen 
sows for their levels of F4-specific IgG and use only piglets that are born to F4 
seronegative mothers, and or we can prescreen the serum and feces of piglets for their 
levels of the F4-specific Ig, eliminating those cohorts with high levels of F4-specific 
antibodies.  
In the current study for statistical purposes we eliminated pigs we deemed 
secondary responders i.e. pigs 429, 430, and 491. The removal of these pigs from the 
analysis allowed us to use only those animals that would elicit primary immune responses 
and not anamnestic ones after F4-loop immunization. Interestingly, their removal did not 
affect the outcome of the analysis regarding the effect of dose on the F4-specific immune 
response, or the relationship observed between the expression level of the F4R and the 
F4-specific immune response. Conversely another group of pigs, the F4Rneg pigs, were 
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important cohorts for our statistical analysis because they provided us with data that 
reflected how the presence of the F4R was integral for eliciting F4-specific immune 
responses in the loops. Moreover our study revealed these pigs elicited F4-specific 
immune responses after immunization with crude F4 protein, thus they were included in 
our analysis regarding the expression level of the F4R and the F4-specific immune 
response.   
Some question however existed as to whether a mucus form of the F4R could be 
acting as a sink, sequestering the F4 Ag in the loops of F4Rneg pigs thereby inhibiting 
their abilty to elicit F4-specific immune responses. However since no F4R exists on the 
enterocytes of F4Rneg pigs, the source of the F4R in mucus is thereby removed 
eliminating this as a reason for the hyporesponsiveness seen in F4Rneg pigs after 
immunization with the F4 Ag 24. Therefore an F4R independent mechanism regarding the 
uptake of the F4 Ag and induction of the F4-specific immune response in F4Rneg pigs 
could be explained through an M cell mediated pathway. Thus once Ag is taken up in the 
PPs of these pigs, DCs located in the dome region of the follicle associated epithelium 
(FAE) capture the F4 Ag and subsequently migrate to the interfollicular region, or the 
mesenteric lymph nodes, where they can induce an immune response 136.  
In contrast, the F4R mod-high pigs likely utilize the F4R and PP for a synergistic 
effect regarding F4 Ag uptake and induction of the F4-specific immune response. This is 
evident as data from our gut-loop experiments demonstrated that only loops with 
moderate to high levels of the F4R + PPs but not loops with only PPs, elicited high 
numbers of F4-specific ASCs. Moreover, Salles et al. 2005 showed that interspaces 
(devoid of PPs) in F4Rmod-high pigs but not F4Rlow-neg pigs, elicited high numbers of F4-
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specific ASCs after immunization with the crude F4 protein. Thus, it appears that the F4R 
is critical for the induction of F4-specific immunity; however, its exact role as a mediator 
of this process is still unknown. Therefore, we can only now speculate as to its 
mechanism. 
A possible mechanism of induction of F4-specific immunity could be that the F4R 
on enterocytes binds the F4 fimbriae, (26 Kd), and participates in a clatherin mediated 
pathway of endocytosis of the F4 Ag, analogous to the uptake of Apo B-100 (30 Kd) by 
the low density lipoprotein receptor located in the liver 142. This method of uptake could 
allow intestinal epithelial cells to participate as Ag presenting cells that pass the F4 Ag to 
DCs in the lamina propria, inducing an F4-specific immune response. However since 
porcine enterocytes do not possess MHC class II molecules, this mechanism may not be 
an efficient way to induce F4-specific immunity 143.  
Another scenario involving the F4R would be if iDCs sample tethered F4 protein 
from intestinal enterocytes. Evidence to support DC sampling of Ag in the intestinal 
lumen comes from studies done in mice. Rescigno et al. (2001) found that DCs could 
extend their dendrites through the tight junctions of intestinal epithelial cells to sample 
bacteria present in the lumen in a process dependant upon their production of the tight 
junction proteins occludin, claudin 1, and zonula occludens 1 55. Furthermore, Niess et al. 
(2005) recently described a subset of murine DCs expressing the chemokine receptor 
CX3CR1 that form transepithelial dendrites in response to the chemokine 
CX3CL1/fractalkine produced by intestinal epithelial cells. However, CX3CL1 is 
expressed at its highest levels in the ileum, and these CX3CR1 expressing DCs are 
believed to be important for the clearance of entero-invasive pathogens such as 
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Salmonella typhimurium 56. Thus, it is possible that similar subsets of DCs exist  that are 
capable of sampling F4 Ag from the lumen of F4Rpos pigs and presenting F4 Ag to 
lymphocytes in the PPs and or mesenteric lymph nodes. This makes the F4R an integral 
component in DC sampling by functioning to make F4 Ag uptake more efficient.   
This was evident in our loops as more F4R in a loop typically translated into 
higher numbers of F4-specific ASCs after F4 immunization. Therefore increasing the 
dose should have resulted in greater F4 binding to the F4R leading to more Ag sampling 
resulting in higher F4-specific immune responses. Interestingly, our statistical analysis 
revealed that after taking into account the expression level of the F4R, and dose, the 
event of immunization rather than the concentration of the F4 protein was important for 
eliciting an F4-specific immune response in the loops. Therefore, in order to enhance the 
F4-specific immune response in our gut-loops perhaps an adjuvant was needed.  
To this end we proposed to enhance the local F4-specific immune response in our 
gut-loops by using the adjuvant CpG ODN. Unfortunately, CpG ODN did not increase 
the F4-specific immune response in our gut-loops. However, Mutwiri et al. (2002) using 
sheep gut-loops, demonstrated that CpG ODN coadministered with porcine serum 
albumin (PSA) enhanced the PSA-specific immune response in these loops. Furthermore 
they showed that CpG ODN was effective at 500µg when coinjected with PSA into the 
loops 89. Therefore, we decided to use 500 µg in our pig gut-loops. Unfortunately, the 
class B CpG ODN 2007 used in our gut-loop experiment did not have an 
immunoenhancing effect. This could have been due to 500µg being an ineffectual dose, 
or the need for CpG ODN + F4 to be co delivered within some sort of delivery vehicle 
such as a liposome or Poly (DL-lactic-co-glycolic acid),  shown by others to enhance the 
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immunostimulatory activity of CpG 144, 145. Furthermore, kinetic studies may need to be 
carried on CpG ODN in our loops out so as to determine an optimum time point for 
harvesting our loops after its co-injection with the F4. Therefore, in order to potentially 
obtain an adjuvant effect from CpG ODN in future pig gut-loop experiments we may 
need to incorporate some or all of the measures noted above. 
Similarly, pBD-1 was ineffective at enhancing the F4-specific immune response 
in the loops when co-administered with the F4 Ag. We expected pBD-1 to enhance the 
F4-specific immune response by 1) chemoattracting more iDCs to sample luminal F4 Ag 
and 2) promote iDC maturation, thereby increasing the number of mature DCs migrating 
to the PPs or mesenteric lymph nodes to present the F4 Ag more effeciently. However, it 
appeared that co-administration of the F4 + pBD-1 in our loops was ineffective at the 
dose tested. Therefore, like CpG ODN we may need to co-deliver the F4 and pBD-1 
within a novel delivery vehicle so as to increase its supposedly short lifetime of activity 
in vivo i.e 4-6 hours 30. The short life-time of pBD-1 in vivo could mean that it might be 
enhancing the F4-specific immune response shortly after immunization requiring us to 
harvest our loops at earlier time intervals, perhaps between 14-21 days post immunization 
in order to detect a response. Furthermore, we could also link the F4 to pBD-1 creating a 
fusion peptide. Thereby bringing the F4 and adjuvant closer together, creating a unique 
spatial and temporal effect regarding uptake of the F4 Ag and activation of iDCs. Thus, 
we cannot conclude that the adjuvants CpG ODN and pBD-1 are inefficacious to enhance 
F4-specific immunity in pigs, until further testing employing the methods above are tried.   
Nevertheless, we currently have no adjuvant that can be administered orally with 
the crude F4 fimbrial protein that can elicit herd immunity against PWC within a group 
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of pigs. Thus, new vaccination strategies are needed that can elicit strong F4-specific 
immune responses in all pigs without the presence of the F4R. One strategy could involve 
the use of a viral vector containing the F4 Ag that could target and enter enterocytes 
independent of the F4R leading to copious amounts of F4 Ag expression and  high F4-
specific intestinal immune responses. Thus, novel strategies such as this to combat enteric 
infections caused by E.coli could be tested in the pig first, and if successful used in other 
species to prevent ETEC infection.  
Specifically, consider the disease known as Traveler’s diarrhea in humans, like 
PWC is caused by E.coli that use fimbriae known as colony forming Ags (CFAs) to 
facilitate adherence and colonization of the intestine 146. It is unknown if the enterocyte 
receptor for the CFA is variably expressed across the human population like the F4R is in 
pigs. However if a similarity exists, then orally vaccinating humans with a CFA based 
vaccine to prevent Traveller’s diarrhea may not be effective due to the inability to 
generate good immune responses in those individuals with low to moderate expression 
levels of the CFA receptor in their small intestine. Therefore ETEC will persist in the 
environment i.e in feces and contaminated water, maintaining infectivity. Thus the pig 
model is able to teach us some valuable lessons for developing vaccines against E.coli 
that can cause enteric infections in humans and other species. 
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7. APPENDIX  
 
 
 
 
7.1 STATISTICAL ANALYSIS 
 
Analysis 1. All loops from 21 pigs were examined for the effect of dose 
(0, 50, 125, 250, & 500 ug/ml F4) and the expression level of the F4R 
as determined by the in vitro villous assay (IVVA) on the F4-specific 
immune response measured by taking the log of the F4-specific IgA 
antibody secreting cells (ASC) isolated from Peyers patches. 
  
Result – Both dose (p < 0.0001) and IVVA (P<0.0001) were significantly 
associated with the log of the F4-specific IgA immune response (R-
squared = 41%). i.e. 41% of the variability in the F4-specific log of 
IgA-ASC is explained by the dose and IVVA categories. 
 
UNWEIGHTED LEAST SQUARES LINEAR REGRESSION OF LOGIGA   
 
PREDICTOR 
VARIABLES    COEFFICIENT    STD ERROR     STUDENT'S T       P       VIF 
---------    -----------    ---------     -----------    ------    ----
- 
CONSTANT        0.11962       0.09950         1.20       0.2318 
DOSE            0.00236     3.445E-04         6.86       0.0000      
1.0 
IVVA            0.01243       0.00270         4.61       0.0000      
1.0 
 
R-SQUARED           0.4191      RESID. MEAN SQUARE (MSE)    0.37507 
ADJUSTED R-SQUARED  0.4086      STANDARD DEVIATION          0.61243 
 
SOURCE        DF       SS           MS         F        P 
----------   ---   ----------   ----------   -----   ------ 
REGRESSION     2     30.0373      15.0187    40.04   0.0000 
RESIDUAL     111     41.6327      0.37507 
TOTAL        113     71.6700 
 
CASES INCLUDED 114   MISSING CASES 0
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50 µg loop
250 µg loop
125 µg loop
0 µg/loop
500 µg loop
Dose of F4
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Analysis 2. All pigs were examined except those which had previously 
been exposed to ETEC F4, and thus had immune responses in their control 
loops. These pigs were therefore categorized as secondary (2o) 
responders. The 2o responders (cohorts 429, 430, 491) were removed from 
the analysis to see the effect of dose and IVVA on the log of the F4-
specific IgA immune response. 
 
Result – The removal of 2o responders shows that both dose (p < 0.0001) 
and IVVA (P<0.0001) were significantly associated with the log of the 
F4-specific IgA-ASC immune response. R-squared = 42%, thus the change 
was minimal relative to analysis 1.   
 
UNWEIGHTED LEAST SQUARES LINEAR REGRESSION OF LOG IgA   
 
PREDICTOR 
VARIABLES    COEFFICIENT    STD ERROR     STUDENT'S T       P       VIF 
---------    -----------    ---------     -----------    ------    ----
- 
CONSTANT        0.11431       0.10313         1.11       0.2704 
DOSE            0.00240     3.570E-04         6.72       0.0000      
1.0 
IVVA            0.01114       0.00280         3.98       0.0001      
1.0 
 
R-SQUARED           0.4267      RESID. MEAN SQUARE (MSE)    0.38728 
ADJUSTED R-SQUARED  0.4150      STANDARD DEVIATION          0.62232 
 
SOURCE        DF       SS           MS         F        P 
----------   ---   ----------   ----------   -----   ------ 
REGRESSION     2     28.2515      14.1257    36.47   0.0000 
RESIDUAL      98     37.9539      0.38728 
TOTAL        100     66.2054 
 
CASES INCLUDED 101   MISSING CASES 0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
50 µg loop
250 µg loop
125 µg loop
0 µg/loop
500 µg loop
Dose of F4
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Analysis 3. All loops from 21 pigs were examined for the effect of dose 
and IVVA on the F4-specific immune response measured by taking the log 
of the F4-specific IgG ASC. 
 
Result – Both dose (p < 0.0001) and IVVA (P < 0.0001) are significantly 
associated with the log of the F4-specific IgG ASCs. R-squared = 32%.  
 
 
UNWEIGHTED LEAST SQUARES LINEAR REGRESSION OF LOG IgG   
 
PREDICTOR 
VARIABLES    COEFFICIENT    STD ERROR     STUDENT'S T       P       VIF 
---------    -----------    ---------     -----------    ------    ----
- 
CONSTANT        0.23728       0.10922         2.17       0.0319 
DOSE            0.00199     3.781E-04         5.26       0.0000      
1.0 
IVVA            0.01289       0.00296         4.36       0.0000      
1.0 
 
R-SQUARED           0.3319      RESID. MEAN SQUARE (MSE)    0.45193 
ADJUSTED R-SQUARED  0.3199      STANDARD DEVIATION          0.67226 
 
SOURCE        DF       SS           MS         F        P 
----------   ---   ----------   ----------   -----   ------ 
REGRESSION     2     24.9197      12.4598    27.57   0.0000 
RESIDUAL     111     50.1642      0.45193 
TOTAL        113     75.0839 
 
CASES INCLUDED 114   MISSING CASES 0 
 
 
 
50 µg loop
250 µg loop
125 µg loop
0 µg/loop
500 µg loop
Dose of F4
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Analysis 4. The 2o responders were removed from the analysis to see the 
effect of dose and IVVA on the log of the F4-specific IgG immune 
response. 
 
Result – Removal of secondary responders does not result in a 
substantial change of the results reported in analysis 3. Both dose (p 
< 0.0001) and IVVA (P < 0.0001) are significantly associated with the 
log of the F4-specific IgG ASCs. R-squared = 34%.  
 
 
UNWEIGHTED LEAST SQUARES LINEAR REGRESSION OF LOG IgG   
 
PREDICTOR 
VARIABLES    COEFFICIENT    STD ERROR     STUDENT'S T       P       VIF 
---------    -----------    ---------     -----------    ------    ----
- 
CONSTANT        0.20517       0.10930         1.88       0.0635 
DOSE            0.00199     3.783E-04         5.27       0.0000      
1.0 
IVVA            0.01223       0.00296         4.13       0.0001      
1.0 
 
R-SQUARED           0.3567      RESID. MEAN SQUARE (MSE)    0.43497 
ADJUSTED R-SQUARED  0.3436      STANDARD DEVIATION          0.65953 
 
SOURCE        DF       SS           MS         F        P 
----------   ---   ----------   ----------   -----   ------ 
REGRESSION     2     23.6398      11.8199    27.17   0.0000 
RESIDUAL      98     42.6275      0.43497 
TOTAL        100     66.2673 
 
CASES INCLUDED 101   MISSING CASES 0 
 
 
 
50 µg loop
250 µg loop
125 µg loop
0 µg/loop
500 µg loop
Dose of F4
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Analysis 5. For all cohorts the non-immunized loops were removed from the 
data set to permit the examination of the effect of dose and IVVA on 
the log of the F4-specific IgA in immunized loops only. Interestingly 
increased doses of F4 Ag was not always associated with an upward shift 
in the dose response curve (i.e. the order from lowest to highest curve 
was 0, 50, 250, 500, and 125). Therefore, these findings suggest that 
the effect of dose was inconsequential to the strength of the F4-
specific immune response. Rather it was important if the loop was 
immunized with the F4 Ag as apposed to not being vaccinated with the 
protein.   
 
Result – Using only the data from loops administered various doses of 
F4 AG, only the IVVA (P < 0.0001) was significantly associated with the 
log of the IgA-ASC immune response. R-squared = 41%. Dose however was 
not associated with the log of the IgA-ASC immune response (P = 0.13). 
Removal of the non-immunized loops did not change the R-squared value. 
 
PREDICTOR 
VARIABLES    COEFFICIENT    STD ERROR     STUDENT'S T       P       VIF 
---------    -----------    ---------     -----------    ------    ----
- 
CONSTANT        0.49127       0.12001         4.09       0.0001 
DOSE          6.124E-04     4.015E-04         1.53       0.1314      
1.1 
IVVA            0.01977       0.00296         6.67       0.0000      
1.1 
 
R-SQUARED           0.4238      RESID. MEAN SQUARE (MSE)    0.31366 
ADJUSTED R-SQUARED  0.4084      STANDARD DEVIATION          0.56005 
 
SOURCE        DF       SS           MS         F        P 
----------   ---   ----------   ----------   -----   ------ 
REGRESSION     2     17.2991      8.64956    27.58   0.0000 
RESIDUAL      75     23.5244      0.31366 
TOTAL         77     40.8235 
 
CASES INCLUDED 78   MISSING CASES 0 
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Analysis 6. For all cohorts the non-immunized loops were removed from 
the data set to examine the effect of dose and IVVA on the log of the 
F4-specific IgG immune response.  
 
Result – Using only the data from loops administered various doses of 
F4 AG, only the IVVA (P < 0.0001) was significantly associated with the 
log of the IgG-ASC immune response. R-squared = 36%. Dose however was 
not associated with the log of the IgG-ASC immune response (P = 0.87). 
Removal of the non-immunized loops did change the R-squared value. 
 
UNWEIGHTED LEAST SQUARES LINEAR REGRESSION OF LOG IgG   
 
PREDICTOR 
VARIABLES    COEFFICIENT    STD ERROR     STUDENT'S T       P       VIF 
---------    -----------    ---------     -----------    ------    ----
- 
CONSTANT        0.71710       0.12326         5.82       0.0000 
DOSE         -6.575E-05     4.124E-04        -0.16       0.8738      
1.1 
IVVA            0.02009       0.00304         6.60       0.0000      
1.1 
 
R-SQUARED           0.3792      RESID. MEAN SQUARE (MSE)    0.33087 
ADJUSTED R-SQUARED  0.3627      STANDARD DEVIATION          0.57522 
 
SOURCE        DF       SS           MS         F        P 
----------   ---   ----------   ----------   -----   ------ 
REGRESSION     2     15.1611      7.58055    22.91   0.0000 
RESIDUAL      75     24.8155      0.33087 
TOTAL         77     39.9766 
 
CASES INCLUDED 78   MISSING CASES 0 
 
 
 
 
50 µg loop
250 µg loop
125 µg loop
500 µg loop
Dose of F4
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Analysis 7. All cohorts were examined regarding the effect of dose on the 
F4-specific IgA-ASC immune response, using Kruskal-Wallis nonparametric 
one-way ANOVA.  
 
Result – Only the non-immunized (dose of 0 ug/ml F4 Ag) loops were 
noticeably different in the strength of their F4-specific IgA-ASC 
immune response relative to immunized loops (50, 125, 250, and 500 
ug/ml F4 Ag). Amongst immunized loops, there was no significant 
difference in the F4-specific IgA-ASC immune response.  
 
KRUSKAL-WALLIS ONE-WAY NONPARAMETRIC AOV FOR IgA BY DOSE 
 
              MEAN    SAMPLE 
   DOSE       RANK     SIZE 
---------    ------   ------ 
     0        27.9      36 
    50        63.5      10 
   125        66.0      40 
   250        76.9      10 
   500        83.8      18 
TOTAL         57.5     114 
 
KRUSKAL-WALLIS STATISTIC                     50.7451 
P-VALUE, USING CHI-SQUARED APPROXIMATION      0.0000 
 
PARAMETRIC AOV APPLIED to RANKS 
 
SOURCE    DF       SS         MS        F       P 
-------  ----  ---------  ---------  ------  ------ 
BETWEEN    4     51032.1    12758.0   22.21  0.0000 
WITHIN   109     62606.9    574.375 
TOTAL    113      113639 
 
TOTAL NUMBER OF VALUES THAT WERE TIED   77 
MAX. DIFF. ALLOWED BETWEEN TIES    0.00001 
 
CASES INCLUDED 114    MISSING CASES 0 
 
COMPARISONS OF MEAN RANKS OF IGA BY DOSE 
 
               MEAN    HOMOGENEOUS 
   DOSE        RANK    GROUPS 
---------  ----------  ----------- 
   500        83.778    I 
   250        76.900    I 
   125        66.000    I 
    50        63.450    I 
     0        27.875   .. I 
 
THERE ARE 2 GROUPS IN WHICH THE MEANS ARE 
NOT SIGNIFICANTLY DIFFERENT FROM ONE ANOTHER. 
 
REJECTION LEVEL    0.050 
CRITICAL Z VALUE    2.81 
CRITICAL VALUES OF DIFFERENCES VARY BETWEEN 
COMPARISONS BECAUSE OF UNEQUAL SAMPLE SIZES.
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Analysis 8. All cohorts were examined regarding the effect of dose on 
the F4-specific IgG-ASC immune response, using Kruskal-Wallis 
nonparametric one-way ANOVA.  
 
Result – Only the non-immunized (dose of 0 ug/ml F4 Ag) loops were 
noticeably different in the strength of their F4-specific IgG-ASC 
immune response relative to immunized loops (50, 125, 250, and 500 
ug/ml F4 Ag). Amongst immunized loops, there was no significant 
difference in the F4-specific IgG-ASC immune response.  
 
KRUSKAL-WALLIS ONE-WAY NONPARAMETRIC AOV FOR IgG BY DOSE 
 
              MEAN    SAMPLE 
   DOSE       RANK     SIZE 
---------    ------   ------ 
     0        26.9      36 
    50        65.8      10 
   125        69.9      40 
   250        72.5      10 
   500        78.1      18 
TOTAL         57.5     114 
 
KRUSKAL-WALLIS STATISTIC                     48.8963 
P-VALUE, USING CHI-SQUARED APPROXIMATION      0.0000 
 
PARAMETRIC AOV APPLIED to RANKS 
 
SOURCE    DF       SS         MS        F       P 
-------  ----  ---------  ---------  ------  ------ 
BETWEEN    4     50341.6    12585.4   20.79  0.0000 
WITHIN   109     65998.4    605.490 
TOTAL    113      116340 
 
TOTAL NUMBER OF VALUES THAT WERE TIED   78 
MAX. DIFF. ALLOWED BETWEEN TIES    0.00001 
 
CASES INCLUDED 114    MISSING CASES 0 
 
COMPARISONS OF MEAN RANKS OF IGG BY DOSE 
 
               MEAN    HOMOGENEOUS 
   DOSE        RANK    GROUPS 
---------  ----------  ----------- 
   500        78.083    I 
   250        72.550    I 
   125        69.900    I 
    50        65.800    I 
     0        26.944   .. I 
 
THERE ARE 2 GROUPS IN WHICH THE MEANS ARE 
NOT SIGNIFICANTLY DIFFERENT FROM ONE ANOTHER. 
 
REJECTION LEVEL    0.050 
CRITICAL Z VALUE    2.81 
CRITICAL VALUES OF DIFFERENCES VARY BETWEEN 
COMPARISONS BECAUSE OF UNEQUAL SAMPLE SIZES.
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Analysis 9. Descriptive statistics for the F4-specific IgA-ASC seen in 
loops as a function of dose. All pigs were included.    
 
Result – As the dose was increased from 0 to 500 ug/ml of F4 Ag, the 
F4-specific IgA- ASC response also increased. However based on analysis 
7, non-immunized loops demonstrated significantly lower responses than 
did the immunized loops. However, the differences among the immunized 
loops were not statistically significant.    
 
DESCRIPTIVE STATISTICS FOR DOSE = 0 
 
VARIABLE    1ST QUARTI      MEDIAN  3RD QUARTI 
IGA             0.0000      0.0000      0.0000 
 
 
DESCRIPTIVE STATISTICS FOR DOSE = 50 
 
VARIABLE    1ST QUARTI      MEDIAN  3RD QUARTI 
IGA             4.5000      10.500      21.250 
 
 
DESCRIPTIVE STATISTICS FOR DOSE = 125 
 
VARIABLE    1ST QUARTI      MEDIAN  3RD QUARTI 
IGA             3.7500      14.000      27.750 
 
 
DESCRIPTIVE STATISTICS FOR DOSE = 250 
 
VARIABLE    1ST QUARTI      MEDIAN  3RD QUARTI 
IGA             2.2500      41.000      115.75 
 
 
DESCRIPTIVE STATISTICS FOR DOSE = 500 
 
VARIABLE    1ST QUARTI      MEDIAN  3RD QUARTI 
IGA             9.0000      55.500      142.00 
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Analysis 10. Descriptive statistics for the F4-specific IgG-ASC seen in 
loops as a function of dose. All pigs were included.    
 
Result – As the dose was increased from 0 to 500 ug/ml of F4 Ag, the 
F4-specific IgG- ASC response also increased.  However, only non-
immunized loops were significantly lower than all other immunized 
loops. Among immunized loops no statistically significant difference in 
the F4-specific IgG-ASC immune response occurred. 
 
DESCRIPTIVE STATISTICS FOR DOSE = 0 
 
VARIABLE    1ST QUARTI      MEDIAN  3RD QUARTI 
IGG             0.0000      0.0000      0.0000 
 
 
DESCRIPTIVE STATISTICS FOR DOSE = 50 
 
VARIABLE    1ST QUARTI      MEDIAN  3RD QUARTI 
IGG             3.7500      13.000      54.250 
 
 
DESCRIPTIVE STATISTICS FOR DOSE = 125 
 
VARIABLE    1ST QUARTI      MEDIAN  3RD QUARTI 
IGG             4.0000      19.500      53.750 
 
 
DESCRIPTIVE STATISTICS FOR DOSE = 250 
 
VARIABLE    1ST QUARTI      MEDIAN  3RD QUARTI 
IGG             7.5000      30.500      54.500 
 
 
DESCRIPTIVE STATISTICS FOR DOSE = 500 
 
VARIABLE    1ST QUARTI      MEDIAN  3RD QUARTI 
IGG             8.0000      34.000      113.25 
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Analysis 11. All pigs except 2o responders were examined for the effects 
of dose, IVVA and maternal antibody on the F4-specific log of the IgA-
ASC response. 
 
Result - After accounting for the effects of both the IVVA and dose, 
there was a significant effect of the maternal antibody concentration 
upon the log of the F4-specific IgA-ASC seen in the loops (P = 0.004). 
For each log increase in maternal antibody, the IgA-ASC content of the 
loops decreased by 0.46 logs (see coefficient for logMA – the log of 
the maternal antibody concentration) 
 
UNWEIGHTED LEAST SQUARES LINEAR REGRESSION OF LOG IgA   
 
PREDICTOR 
VARIABLES    COEFFICIENT    STD ERROR     STUDENT'S T       P       VIF 
---------    -----------    ---------     -----------    ------    ----
- 
CONSTANT        0.93317       0.29662         3.15       0.0022 
DOSE            0.00252     3.465E-04         7.28       0.0000      
1.0 
IVVA            0.01080       0.00270         4.00       0.0001      
1.0 
LOGMA          -0.45805       0.15634        -2.93       0.0042      
1.0 
 
R-SQUARED           0.4733      RESID. MEAN SQUARE (MSE)    0.35947 
ADJUSTED R-SQUARED  0.4570      STANDARD DEVIATION          0.59956 
 
SOURCE        DF       SS           MS         F        P 
----------   ---   ----------   ----------   -----   ------ 
REGRESSION     3     31.3371      10.4457    29.06   0.0000 
RESIDUAL      97     34.8682      0.35947 
TOTAL        100     66.2054 
 
CASES INCLUDED 101   MISSING CASES 0 
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Analysis 12. All pigs except 2o responders were examined for the effects 
of dose, IVVA and maternal antibody on the F4-specific log of the IgG-
ASC response. 
 
Result - After accounting for the effects of both the IVVA and dose, 
there was a trend for the maternal antibody concentration to affect the 
log of the F4-specific IgG-ASC seen in the loops (P = 0.09). For each 
log increase in maternal antibody, the IgG-ASC content of the loops 
decreased by 0.30 logs (see coefficient for logMA – the log of the 
maternal antibody concentration) 
 
UNWEIGHTED LEAST SQUARES LINEAR REGRESSION OF LOG IgG   
 
PREDICTOR 
VARIABLES    COEFFICIENT    STD ERROR     STUDENT'S T       P       VIF 
---------    -----------    ---------     -----------    ------    ----
- 
CONSTANT        0.73464       0.32297         2.27       0.0251 
DOSE            0.00207     3.773E-04         5.50       0.0000      
1.0 
IVVA            0.01201       0.00294         4.09       0.0001      
1.0 
LOGMA          -0.29617       0.17022        -1.74       0.0851      
1.0 
 
R-SQUARED           0.3762      RESID. MEAN SQUARE (MSE)    0.42616 
ADJUSTED R-SQUARED  0.3569      STANDARD DEVIATION          0.65281 
 
SOURCE        DF       SS           MS         F        P 
----------   ---   ----------   ----------   -----   ------ 
REGRESSION     3     24.9299      8.30996    19.50   0.0000 
RESIDUAL      97     41.3375      0.42616 
TOTAL        100     66.2673 
 
CASES INCLUDED 101   MISSING CASES 0 
 
 
 
